Subcutaneous formulations of anti-CD38 antibodies and their uses

Patent Citations (231)

Non-Patent Literature (760)

• “A Prospective Phase II of Daratumumab in Previously Treated Systemic Light Chain (AL) Amyloidosis”, published online at //cms.cws.net/content/beta.myelomasociety.org/files/2017ash/Roussel,%20Murielle-ASH2017.pdf (2017).Applicant
• Aarhust, et al., “ADP-ribosyl Cyclase and CD38 Catalyze the Synthesis of a Calcium mobilizing Metabolite from NADP+,” The Journal of Biological Chemistry, 270(51): 30327-30333 (1995).Applicant
• Abdi, J. et al., “Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms,” Oncotarget, vol. 4; No. 12; 2186-2207 (2013).Applicant
• Adriouch et al., “Extracellular NAD+: a danger signal hindering regulatory T cells,” Microbes and Infection, 14:1284-1292 (2012).Applicant
• Agheli, A. et al., “A Rare Case of Primary Amyloidosis, Presenting with Severe Pulmonary Hypertension and Bilateral Pleural Effusion,” Blood, vol. 106: p. 5100 (2005).Applicant
• Almagro, J.C. and Fransson, J., “Humanization of antibodies,” Frontiers in Bioscience, vol. 13; 1619-1633 (2008).Applicant
• Arican, et al., “Philadelphia Chromosome (+) T-Cell Acute Lymphoblastic Leukemia After Renal Transplantation,” Transplantation Proceedings, vol. 31; 3242-3243 (1999).Applicant
• Armitage et al., “Long-Term Remission Durability and Functional Status of Patients Treated for Diffuse Histiocytic Lymphoma with the CHOP Regimen,” J. Clin. Oncol. 2:898-902, (1984).Applicant
• Arthur, “Innovations in subcutaneous infusions,” J. Infus. Nurs. 38(3); 179-87; May/Jun. 2015.Applicant
• ASH Clinical News, “Is Daratumumab Plus Lenalidomide-Dexamethasone a New Standard for Transplant-Ineligible Myeloma,” Dated Jan. 1, 2019, Retrieved from Internet URL: https://www.ashclinicalnews.org/on-location/ash-annual-meeting/daratumumab-plus-lenalidomid; Retrieved Oct. 28, 2022 (2 pages).Applicant
• AstraZeneca 206162 Clinical Pharmacology Review 2014, (https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/206162Orig1s000ClinPharmR.pdf; Application No. 206162Orig1s000; 117 pages.Applicant
• Avet-Loiseau, H. et al., “Evaluation of Minimal Residual Disease (MRD) in Relapsed/Refractory Multiple Myeloma (RRMM) Patients Treated with Daratumumab in Combination with Lenalidomide Plus Dexamethasone or Bortezomib Plus Dexamethasone,” Blood, vol. 128; No. 22; 246; 7 pages (2016).Applicant
• Bachireddy, et al., “Haematologic Malignancies: at the Forefront of Immunotherapeutic Innovation,” Nature Reviews Cancer, vol. 15, No. 4, pp. 201-215, Apr. 1, 2015 (Apr. 1, 2015).Applicant
• Bahlis, N.J. et al., “Daratumumab, lenalidomide, and dexamethasone (DRd) vs lenalidomide and dexamethasone (Rd) in relapsed or refractory multiple myeloma (RRMM): Efficacy and safety updated (POLLUX),” Journal of Clinical Oncology, vol. 35; No. 15; 8025; Abstract (2017).Applicant
• Bauer, Fromming, Fuhrer, “Lehrbuch der Pharmazeutischen Technologie” 8th Edition, Wissenschaftliche Verlagsgesellschaft Stuttgart, Chapter 9; 238-243 (2006). (concise explanation met by submission of the enclosed Opponent's submission filed by Dr. Markus Breuer, dated Oct. 4, 2022, cited as Other Document 410).Applicant
• BC Cancer Agency Cancer drug Manual, Oct. 1, 2013, “Hydroxyurea”. http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Hydroxyurea_monograph_1Oct2013.pdf; Retrieved on Nov. 20, 2023; 7 pages (No Author given).Applicant
• Berglund, L. et al., “The epitope space of the human proteome,” Protein Science, vol. 17; 606-613 (2008).Applicant
• Bittner, B. et al., “Development of a Subcutaneous Formulation for Trastuzumab—Nonclinical and Clinical Bridging Approach to the Approved Intravenous Dosing Regimen,” Arzneimittelforschung, vol. 62; 401-409 (2012).Applicant
• Bittner, B. et al., “Non-Clinical Pharmacokinetic /Pharmacodynamic and Early Clinical Studies Supporting Development of a Novel Subcutaneous Formulation for the Monoclonal Antibody Rituximab,” Drug Res., vol. 64; 569-575 (2014).Applicant
• Bittner, B. et al., “Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities,” BioDrugs, vol. 32; 425-440 (2018).Applicant
• Blankestijn, et al., “Could daratumumab be used to treat severe allergy?,” Journal of Allergy and Clinical Immunology, Elsevier, Amsterdam, NL, vol. 139, No. 5, p. 1677-1678, Jan. 19, 2017.Applicant
• Bookbinder, L.H. et al., “A recombinant human enzyme for enhanced interstitial transport of therapeutics,” Journal of Controlled Release, vol. 114; 230-241 (2006).Applicant
• Brand, F-X. et al., “Prospect for Anti-HER2 Receptor Therapy in Breast Cancer,” AntiCancer Research, vol. 26; 463-470 (2006).Applicant
• Brown, et al., “Tolerance of single, but not multiple, amino acid replacements in antibody VH CDR 2: a means of minimizing B cell wastage from somatic hypermutation?” The Journal of Immunology, 156: 3285-3291 (1996).Applicant
• Carter et al., “Identification and validation of cell surface antigens for antibody targeting in oncology,” Endocrine-Related Cancer, vol. 11, pp. 659-687, (2004).Applicant
• CAS Registry Results, dated Oct. 9, 2020, Registry No. 757971-58-7, “36-482-Hyaluronoglucosaminidase PH20 (human),” 6 pages.Applicant
• Ceran, C. et al., “Novel anti-HER2 monoclonal antibodies: Synergy and antagonism with tumor necrosis factor-α,” BMC Cancer, vol. 12; No. 450; 16 pages (2012).Applicant
• Chari et al., “Subcutaneous Delivery of Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): PAVO, an Open-label, Multicenter, Dose Escalation Phase 1b Study,” American Society of Hematology, Clinical Trials.gov Identifier NCTO2519452, Dec. 2017.Applicant
• Chari A. et al., “Subcutaneous delivery of daratumumab in patients (pts) with relapsed or refractory multiple myeloma (RRMM): PAVO, an openlabel, multicenter, dose escalation phase 1b study,” 2017 ASH Annual Meeting ANZMAP Multiple Myeloma Highlights, 2017.Applicant
• Chari, A., et al., “Subcutaneous Daratumumab (DARA) in Patients (Pts) With Relapsed or Refractory Multiple Myeloma (RRMM): Part 2 Update of the Open-label, Multicenter, Dose-escalation Phase 1b Study (PAVO)”, Poster Presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO); Jun. 1-5, 2018; Chicago, Illinois.Applicant
• Chaulagain, C.P. et al., “Pre-clinical translational studies of daratumumab in patients with myeloma or AL amyloidosis undergoing autologous hematopoietic stem cell transplantation (SCT),” Journal of Clinical Oncology , May 20, 2015, vol. 33, No. 15 suppl., pp. 8587-8587.Applicant
• Chaulagain, C.P., et al., “How we Treat Systemic Light-Chain Amyloidosis,” Clinical Advances in Hematology & Oncology, vol. 13; No. 5; 315-324 (2015).Applicant
• Chaulagain, C.P. and Comenzo, R.L., “New Insights and Modern Treatment of AL Amyloidosis,” Curr Hematol Malig Rep, vol. 8; 291-298 (2013).Applicant
• Chen, et al., “Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen,” Journal of Molecular Biology, 293: 865-881 (1999).Applicant
• Cheson et al., “Revised Response Criteria for Malignant Lymphoma,” Journal of Clinical Oncology, vol. 25, No. 5, 579-586 (Feb. 10, 2007).Applicant
• Chiarugi, A. et al., “The NAD metabolome—a key determinant of cancel cell biology,” Nature Reviews, vol. 12; 741-752 (2012).Applicant
• Child, J.A. et al, “High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma,” N Engl J Med, vol. 348; 1875-1883 (2003).Applicant
• Chillemi, A. et al., “Anti-CD38 Antibody Therapy: Windows of Opportunity Yielded by the Functional Characteristics of the Target Molecule,” Molecular Medicine, vol. 19; 99-108 (2013).Applicant
• CHMP Assessment Report for Herceptin (trastuzumab), 70 pages (2013).Applicant
• CHMP Assessment Report for Mabthera (rituximab), 103 pages (2014).Applicant
• Chou, et al., “Drug Combination Studies and their Synergy Quantification Using the Chou-Talalay Method,” Cancer Research, 70(2): 440-446 (2010).Applicant
• Chung, C.H., “Managing Premedications and the Risk for Reactions to Infusional Monoclonal Antibody Therapy,” The Oncologist, vol. 13; 725-732 (2008).Applicant
• City of Hope, “What's the Difference? Biosimilar and generic drug,” City of Hope, retrieved from: https://www .cancercenter.com/community/blog/2018/12/whats-the-difference-biosimi lar-and-generic-drugs; 3 Pages (Year: 2018).Applicant
• ClinicalTrials.gov, “Daratumumab in Combination with ATRA (DARA/ATRA),” Identifier: NCT02751255; First posted: Apr. 26, 2016 (11 pages).Applicant
• ClinicalTrials.gov “Study of YM155 in Refractory Diffuse Large B-cell Lymphoma (DLBCL) Subjects,” Interventional Studies, U.S. National Library of Medicine, //clinicaltrials.gov/ct2/show/record/NCT00498914, First posted Jul. 11, 2007 [retrieved on Sep. 10, 2018]. (4 pages).Applicant
• ClinicalTrials.gov, “A Study of Daratumumab with the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma,” Identifier: NCT02519452; First Posted: Aug. 11, 2015 (13 pages).Applicant
• ClinicalTrials.gov, “A Study to Evaluate Subcutaneous Daratumumab in Combination with Standard Multiple Myeloma Treatment Regimens,” Identifier: NCT03412565, First Posted: Jan. 26, 2018 (16 pages).Applicant
• ClinicalTrials.gov, “A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of TAK-079 in Healthy Participants,” Identifier: NCT02219256, 13 pages; Latest version posted: Mar. 22, 2017. (13 pages).Applicant
• ClinicalTrials.gov, “Daratumumab (HuMax-CD38) Safety Study in Multiple Myeloma,” Identifier: NCT00574288; Latest version posted: Apr. 27, 2018 (10 pages).Applicant
• ClinicalTrials.gov, “An Investigational Immuno-Therapy Study to Determine the Safety and Effectiveness of Nivolumab and Daratumumab in Patients with Multiple Myeloma,” Identifier: NCT01592370; Latest version posted: Jun. 18, 2021 (10 pages).Applicant
• ClinicalTrials.gov, “History of Changes for Study: NCT02252172: Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma,” U.S. National Library of Medicine, ClinicalTrials.gov Archive, Oct. 17, 2017 (24 pages).Applicant
• ClinicalTrials.gov, “History of Changes for Study: NCT02519452: A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma,” U.S. National Library of Medicine, ClinicalTrials.gov Archive, Dec. 3, 2020 (12 pages).Applicant
• ClinicalTrials.gov, “A Study of Daratumumab with the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants with Relapsed or Refractory Multiple Myeloma,” Identifier: NCT02519452; First Received: Aug. 6, 2015 (5 pages).Applicant
• ClinicalTrials.gov, “A Study to Evaluate Daratumumab in Transplant Eligible Participants with Previously Untreated Multiple Myeloma (Cassiopeia),” Identifier: NCT02541383; First Posted: Sep. 4, 2015 (29 pages).Applicant
• ClinicalTrials.gov, “Safety and Efficacy Study of Eculizumab in Patients with Refractory Generalized Myasthenia Gravis,” Identifier: NCT00727194; Latest version: Sep. 13, 2019 (6 pages).Applicant
• Colman, “Effects of amino acid sequence changes on antibody-antigen interactions,” A Structural View of Immune Recognition by Antibodies, Biomolecular Research Institute, 33-36, (1994).Applicant
• Colson, K., “Treatment-related symptom management in patients with multiple myeloma: a review,” Support Care Cancer, vol. 23; 1431-1445 (2015).Applicant
• Comenzo, R.L. et al., “Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis,” Leukemia, vol. 26; 2317-2325 (2012).Applicant
• Common Terminology Criteria for Adverse Events (CTCAE), Version 4.03, U.S. Department of Health and Human Services, 4 pages (2010).Applicant
• Complete Specification for Indian Application No. 4718/CHENP/2007; published on Jan. 11, 2008 (225 Pages).Applicant
• Consolidated list of references from Opposition in parent patent EP No. 3370770, 4 pages; Feb. 24, 2022.Applicant
• Cotner, et al., “Human T Cell Proteins Recognized by Rabbit Heteroantisera and Monoclonal Antibodies,” International Journal of Immunopharmaceuticals, 3(3): 255-268 (1981).Applicant
• CureSearch for Children's Cancer, “Relapse of Recurrence,” Retrieved from Internet URL: https://curesearch.org/Relapse-or-Recurrence, 3 pages; Retrieved on Oct. 27, 2022.Applicant
• Darzalex, Highlights and Prescribing Information, FDA Label, 24 pages (2015).Applicant
• Darzalex, Highlights and Prescribing Information, FDA Label, 11 pages (2017).Applicant
• Darzalex, Highlights and Prescribing Information, FDA Label, 32 pages (2018).Applicant
• Data show daratumumab achieved a pronounced overall response rate as a single-agent with tolerable safety profile in heavily pre-treated multiple myeloma patients, Johnson & Johnson Press release [online](retrived on Jul. 27, 2020), May 30, 2015, retrieved from the Internet<URL:https://www.jnj.com/media-center/press-releases/Data-show-daratumumab-achieved-a-pronounced-overall-response-rate-as-a-single-agent-with-tolerable-safety-profile-in-heavily-pre-treated-multiple-myeloma-patients>; 4 pages.Applicant
• Davies, et al., “Affinity improvement of single antibody VH domains: residues in all three hypervariable regions affect antigen binding,” Immunotechnology, 2: 169-179 (1996).Applicant
• Davies, A. et al., “Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (Sabrina): stage 1 analysis of a randomised phase 3 study,” The Lancet, vol. 15; 343-352 (2014).Applicant
• Davies, A. et al., “Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (Sabrina): stage 1 analysis of a randomised phase 3 study,” The Lancet, vol. 15; 343-352 (2014); Supplemental Appendix (8 Pages).Applicant
• Davis, et al., “Transgenic mice as a source of fully human antibodies for the treatment of cancer,” Cancer and Metastasis Reviews, 18: 421-425 (1999).Applicant
• Davis, T.A. et al., “Rituximab Anti-CD20 Monoclonal Antibody Therapy in Non-Hodgkin's Lymphoma: Safety and Efficacy of Re-Treatment,” Journal of Clinical Oncology, vol. 18; No. 17; 3135-3143 (2000).Applicant
• Deckert, et al., “SAR650984, A Novel Humanized CD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in Models of Multiple Myeloma and Other CD38β Hematologic Malignancies,” Clinical Cancer Research. Vol. 20, No. 17, pp. 4574-4583 (2014).Applicant
• Demarest, T.G. et al., “NAD+ Metabolism in Aging and Cancer,” Annual Rev. Cancer Biol., vol. 3; 105-130 (2019).Applicant
• Dennis, “Off by a Whisker,” Nature, 442 (17): 749-741 (2006).Applicant
• DePascalis, et al., “Grafting of ‘Abbreviated’ Complementarity-Determining Regions Containing Specificity-Determining Residues Essential for Ligand Contact to Engineer a Less Immunogenic Humanized Monoclonal Antibody,” The Journal of Immunology, 169: 3076-3084 (2002).Applicant
• De Haart, S.J. et al., “Accessory Cells of the Microenvironment Protect Multiple Myeloma from T-Cell Cytotoxicity through Cell Adhesion-Mediated Immune Resistance,” Clinical Cancer Research, vol. 19; No. 20; 5591-5601 (2013).Applicant
• De Weers, et al., “Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors,” The Journal of Immunology, 186: 1840-1848 (Pre-published online Dec. 27, 2010).Applicant
• De Weers, M. et al., “Humax-CD38, a New Human CD38 Monoclonal Antibody, Effectively Mediates Killing of Multiple Myeloma and Plasma Cell Leukemia Cells,” abstract, Submitted for the 16th European Congress of Immunology—ECI2006, Paris, France, [Sep. 6-9, 2006].Applicant
• De Weers et al., “HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells,” The 23rd International Conference on Advances in the Application of Monoclonal Antibodies in Clinical Oncology, (Jun. 26-28, 2006), Royal Myconian Resort & Thalasso Spa Center, Mykonos, Greece (Abstract).Applicant
• Dimopoulos, M.A. et al., “Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma,” The New England Journal of Medicine, vol. 375; No. 14; 1319-1331 (2016).Applicant
• Dimopoulos, M.A. et al., “Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma,” The New England Journal of Medicine, vol. 375; No. 14; 1319-1331 (2016); Suppl. Material: the protocol; total pages 111 (2016).Applicant
• Dimopoulos, M.A. et al., “Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX,” Haematologica, vol. 103; No. 12; 2088-2096 (2018).Applicant
• Dimopoulos, M.A. et al., “Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (Apollo): an open-label, randomised, phase 3 trial,” Lancet Oncol, vol. 22; 801-812 (2021).Applicant
• Dispenzieri, A. et al., “Treatment of Immunoglobulin Light Chain Amyloidosis: Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Statement,” Mayo Clin Proc., vol. 90; No. 8; 1054-1081 (2015).Applicant
• DMC recommends termination of study into daratumumab with atezolizumab to treat NSCLC, European Pharmaceutic Manufacturer[online](retrieved on Jul. 26, 2020), May 30, 2018, retrieved from the Internet<URL:https://www.epmmagazine.com/news/dmc-recommends-termination-of-study-into-daratumumab/>; 3 pages.Applicant
• Doessegger, L. and Banholzer, M.L., “Clinical development methodology for infusion-related reactions with monoclonal antibodies,” Clinical & Translational Immunology, vol. 4; e39; 9 pages (2015).Applicant
• Dos Santos, et al., Anti-Leukemic Activity of Daratumumab in Acute Myeloid Leukemia Cells and Patient-Derived Xenografts, Blood, vol. 124, Abstract 2312, (2014).Applicant
• Doshi, et al., “Daratumumab Treatment in Combination with Chop or R-Chop Results in the Inhibition or Regression of Tumors in Preclinical Models of Non-Hodgkins Lymphoma,” Haematologica, The Hematology Journal, 99(1): 138 (2014).Applicant
• Drach, J. et al., “Retinoic Acid-induced Expression of CD38 Antigen in Myeloid Cells is Mediated through Retinoic Acid Receptor-α1,” Cancer Research, vol. 54; 1746-1752 (1994).Applicant
• Durie, B.G.M. et al., “International Uniform Response Criteria for Multiple Myeloma,” Leukemia, vol. 20; 1467-1473 (2006).Applicant
• Eldfors, et al., “Landscape of Mutations in Relapsed Acute Myeloid Leukemia,” vol. 124: No. 21, p. 2367; (2014).Applicant
• Ellis, et al., “Engineered Anti-CD38 Monoclonal Antibodies for Immunotherapy of Multiple Myeloma,” The Journal of Immunology, 155: 925-937 (1995).Applicant
• Engert, et al., “A Phase-I Study of an Anti-CD25 Ricin A-Chain Immunotoxin (RFT5-SMPT-dgA) in Patients with Refractory Hodgkin's Lymphoma,” Blood, 89(2): 403-410 (1997).Applicant
• Ettinger, R. et al., “Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses,” Autoimmunity, vol. 50; No. 1; 25-36 (2017).Applicant
• European Medicines Agency, Summary of Product Characteristics for Rituximab; 153 pages; Oct. 30, 2009, https://www.ema.europa.eu/en/documents/product-information/mabthera-epar-product-information_en.pdf.Applicant
• European Union Clinical Trials Register Clinical Trials Register, EudraCT No. 2014-002272-88; Title: “A Phase 3, Randomized, Controlled, Open-label Study of Velcade (Bortezomlb) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), In Subjects with Previously Untreated Multiple Myeloma who are Inellgible for High-dose Therapy,” 6 pages (2015).Applicant
• European Union Clinical Trials Register Clinical Trials Register, EudraCT No. 2014-002273-11; Title: “A Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High Dose Therapy,” 7 pages (2015).Applicant
• European Union Clinical Trials Register Clinical Trials Register, EudraCT No. 2013-005525-23; Title: “Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects with Relapsed or Refractory Multiple Myeloma,” 7 pages (2014).Applicant
• European Union Clinical Trials Register Clinical Trials Register, EudraCT No. 2014-000255-85; Title: “Phase 3 Study Comparing Daratumumab, Bortezomlb and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Subjects With Relapsed or Refractory Multiple Myeloma,” 6 pages (2014).Applicant
• Facon, T. et al., “Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA),” Blood, vol. 132 (Suppl 1); 8 Pages (2018).Applicant
• Faiman, B. et al., “Steroid-Associated Side Effects in Patents with Multiple Myeloma: Consensus Statement of the IMF Nurse Leadership Board,” Clinical Journal of Oncology Nursing, vol. 12; No. 3; 53-63 (2008).Applicant
• Ferrero, et al., Characterization and phylogenetic epitope mapping of CD38 ADPR cyclase in the cynomolgus macaque, BMC Immunology, 5(21): 1-13 (2004).Applicant
• Field-Smith, “Bortezomid (Velcade™) in the treatment of multiple myeloma,” Therapeutic and Clinical Risk Management, 2(3): 271-279 (2006).Applicant
• Flavell, et al., “Therapy of human T-cell acute lymphoblastic leukaemia with a combination of anti-CD7 and anti-CD38-SAPORIN immunotoxins is significantly better than therapy with each individual immunotoxin,” Br. J. Cancer, vol. 84, No. 4, pp. 571-578, (2001).Applicant
• Franco, et al., “The transmembrane glycoprotein CD38 is a catalytically active transporter responsible for generation and influx of the second messenger cyclic ADP-ribose across membranes,” FASEB Journal, 12: 1507-1520 (1998).Applicant
• Freeley et al., “The ‘Ins and Outs’ of complement-driven immune responses”, Immunol Rev., 274(1), pp. 16-32, Nov. 2016.Applicant
• Frost, G.I., “Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration,” Expert Opinion Drug Deliv., vol. 4; No. 4; 427-440 (2007).Applicant
• Fujimori, et al., “A Modeling Analysis of Monoclonal Antibody Percolation Though Tumors: A Binding-Site Barrier,” Journal of Nucleic Medicine, 31: 1191-1198 (1990).Applicant
• Fujioka, Y. and Kurokawa, M., “Follicular lymphoma presenting with massive splenomegaly,” International J Hematol, vol. 95; 3-4 (2012).Applicant
• Funaro et al., “CD38 Functions Are Regulated Through an Internalization Step,” Journal of Immunology, 160: 2238-2247 (1998).Applicant
• Funaro, et al., “Human CD38: a versatile leukocyte molecule with emerging clinical prospectives,” Fundamental and Clinical Immunology, 3(3): 101-113 (1995).Applicant
• Funaro, et al., “Identification and characterization of an active soluble form of human CD38 in normal and pathological fluids,” International Immunology, 8(11): 1643-1650 (1996).Applicant
• Funaro, et al., “Involvement of the Multilineage CD38 Molecule in a Unique Pathway of Cell Activation and Proliferation,” The Journal of Immunology, 145: 2390-2396 (1990).Applicant
• Gallo, et al., “The human immunoglobulin loci introduced into mice: V(D) and J gene segment usage similar to that of adult humans,” European Journal of Immunology, 30: 534-540 (2000).Applicant
• Gariani, K. et al., “Inhibiting poly ADP-ribosylation increases fatty acid oxidation and protects against fatty liver disease,” Journal of Hepatology, vol. 66; 132-141 (2017).Applicant
• Gay, F. and Palumbo, A., “Management of Older Patients with Multiple Myeloma,” Blood Reviews, vol. 25; 65-73 (2011).Applicant
• Genmab “Humanx-CD38 Effective in Preclinical Studies,” Genmab A/S, Stock Exchange Release 57/2005.Applicant
• Genmab “Daratumumab Receives Breakthrough Therapy Designation from US Food and Drug Administration”, Copenhagen, Denmark; May 1, 2013—Genmab A/S (OMX: GEN) disponible en: http://files.shareholder.com/downloads/AMDA-KPIBN/0x0x659093/64b187b8-830c-4252-acd6-8019b4199069/18%20Daratumumab%20breakthrough%20status_010513_uk.pdf, (May 1, 2013).Applicant
• Genmab Announces Daratumumab and Ofatumumab Data to Be Presented at American Society of Hematology Annual Meeting (ASH), American Society of Hematology Annual Meeting and Exposition, San Francisco, California, Media Release 06; pp. 1-3 (Nov. 2014).Applicant
• George, et al., “Differential Effects of Anti-β2-Glycoprotein I Antibodies on Endothelial Cells and on the Manifestations of Experimental Antiphospholipid Syndrome,” Circulation, 97: 900-906 (1998).Applicant
• Goel, M. et al., “Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response,” The Journal of Immunology, vol. 173; 7358-7367 (2004).Applicant
• Goldmacher, et al., “Anti-CD38-Blocked Ricin: An immunotoxin for the Treatment of Multiple Myeloma,” The American Society of Hematology, 84(9): 3017-3025 (1994).Applicant
• Goodwin, “Subcutaneous Daratumumab Potential Game Changer for Multiple Myeloma,” Oncology Times, 2017 American Society of Hematology Annual Meeting, p. 49, (2017).Applicant
• Gopalakrishnan, et al. “Daratumumab improves the anti-myeloma effect of newly emerging multidrug therapies,” Blood and Lymphatic Cancer: Targets and Therapy, 3: 19-24 (2013).Applicant
• Graeff, et al., “Enzymatic Synthesis and Characterizations of Cyclic GDp-ribose,” The Journal of Biological Chemistry, 269(48): 30260-30267 (1994).Applicant
• Green, “Antibody engineering via genetic engineering of the mouse: XenoMouse strains are a vehicle for the facile generation of therapeutic human monoclonal antibodies,” Journal of Immunological Methods, 231: 11-23 (1999).Applicant
• Green, et al., “Antigen-specific human monoclonal antibodies from mice engineered with hyman Ig heavy and light chain YACs,” Nature Genetics, 7: 13-21 (1994).Applicant
• Gupta, R. et al., “The Economic Impact of Childhood Food Allergy in the United States,” JAMA Pediatrics, vol. 167; No. 11; 1026-1031 (2013).Applicant
• Guse et al., “Regulation of calcium signaling in T lymphocytes by the second messenger cyclic ADP-ribose,” Nature 398:70-73, (1999).Applicant
• Haart, et al., “Sepantronium bromide (YM155) improves daratumumab-mediated cellular lysis of multiple myeloma cells by abrogation of bone marrow stromal cell-induced resistance,” Haematologica, Letters to the Editor, vol. 101, No. 8, pp. e339-e343, (2016).Applicant
• Haller, M.F., “Converting Intravenous Dosing to Subcutaneous Dosing,” Pharmaceutical Technology, 118-132 (2007).Applicant
• Halozyme, “Halozyme Therapeutics Reports Selection of First Product Candidate Under Janssen Collaboration,” Press Release, 4 pages (2015).Applicant
• Hamizi, S. et al., “Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer,” OncoTargets and Therapy, vol. 6; 89-94 (2013).Applicant
• Hara-Yokoyama, “Alteration of enzymatic properties of cell-surface antigen CD38 by agonistic anti-CD38 antibodies that prolong B cell survival and induce activation,” International Immunopharmacology, 8: 59-70 (2008).Applicant
• Hartmann, Radioimmunotherapy of Nude Mice Bearing a Human Interleukin 2 Receptor α-expressing Lymphoma Utilizing the α-emitting Radionuclide-conjugated Monoclonal Antibody 212Bi-anti-Tac, Cancer Research, 54: 4362-4370 (1994).Applicant
• Henry, et al., “the use of basiliximab in solid organ transplantation,” Expert Opinion Pharmacotherapy, 3(10): 1657-1663 (2002).Applicant
• Herceptin, Highlights and Prescribing Information, FDA Label, 33 pages (1998).Applicant
• Highlights of Prescribing Information, Rituxan, 53 pages (1997).Applicant
• Highlights of Prescribing Information, Rituxan (rituximab) injection, 44 pages (1997).Applicant
• Holgate, S.T., “New strategies with anti-IgE in allergic diseases,” World Allergy Organization Journal, vol. 7; No. 17; 6 pages (2014).Applicant
• Holm, et al., “Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1,” Molecular Immunology, 44: 1075-1084 (2017).Applicant
• Hoshino, et al., “Mapping of the Catalylic and Epitopic Sites of Human CD38/NAD+ Glycohydrolase to a Functional Domain in the Carboxyl Terminus1,” The Journal of Immunology, 158: 741-747 (1997).Applicant
• Howard, et al., “Formation and Hydrolysis of Cyclic ADP-Ribose Catalyzed by lymphocyte Antigen CD38,” Science, 262(5136): 1056-1059 (1993).Applicant
• Hu, Y., et al., “Immunophenotypic analysis of abnormal plasma cell clones in bone marrow of primary systemic light chain amyloidosis patients,” Chin Med J., vol. 127; No. 15; 2765-2770; Abstract only (2014).Applicant
• Hu, Y. et al., “The Significance of Abnormal Plasma Cell Clone in Bone Marrow of Primary Systemic Light Chain Amyloidosis Patients,” Blood, vol. 122; p. 5342 (2013).Applicant
• Hydase, Highlights and Prescribing Information, FDA Label, 6 pages (2005).Applicant
• Hylenex, Highlights and Prescribing Information, FDA Label, 9 pages (2005).Applicant
• Ikehata, et al., “Autoantibodies against CD38 (ADP-ribosyl Cyclase/Cyclic ADP-ribose Hydrolase) that Impair Glucose-induced Insulin Secretion in Noninsulin-dependent Diabetes Patients,” Journal of Clinical Investigations, 102(2): 395-401 (1998).Applicant
• Inaba, H. et al., “Acute lymphoblastic leukaemia,” Lancet, vol. 381; 27 pages (2013).Applicant
• Jaccard, A. et al., “Efficacy of bortezomib, cyclophosphamide and dexamethasone in treatment-naïve patients with high-risk cardiac AL amyloidosis (Mayo Clinic stage III),” Haematologica, vol. 99; No. 9; 1479-1485 (2014).Applicant
• Jackisch, C. et al., “Subcutaneous Administration of Monoclonal Antibodies in Oncology,” Geburtsh Frauenhelk, vol. 74; 343-349 (2014).Applicant
• Jackisch, et al., “Subcutaneous versus intravenous formulation of trastuzumab for HER2-positive early breast cancer: updated results from the phase III HannaH study,” Annals of Oncology, vol. 26, pp. 320-325, (2015).Applicant
• Jackson, et al., “Isolation of a cDNA Encoding The Human CD38 (T10) molecule, A Cell Surface Glycoprotein With an Unusual Discontinuous Pattern of Expression During Lymphocyte Differentiation,” The Journal of Immunology, 144(7): 2811-2815 (1990).Applicant
• Jagannath, et al. Treatment (tx) journeys in newly diagnosed multiple myeloma (NDMM) patients (pts): Results from the Connect MM Registry. Multiple Myeloma Update from the American Society of Clinical Oncology. (ASCO) 41st Annual meeting, (Jun. 4, 2018).Applicant
• Jakob, et al., “Stage-dependent Expression of CD7, CD45RO, CD45RA and CD25 on CD4-positive Peripheral Blood T-lymphocytes in Cutaneous T-cell Lymphoma,” Acta Derm Venerology, 76: 34-36 (1996).Applicant
• Jakobovits, “the long-awaited magic bullets: therapeutic human monoclonal antibodies from transgenic mice”, Expert Opinion on Investigational Drugs, 7(4): 607-614 (1998).Applicant
• Jang, et al., “The structural basis for DNA binding by an anti-DNA autoantibody,” Molecular Immunology, 35: 1207-1217 (1998).Applicant
• Janssen Initiates Rolling Submission of Biologic License Application (BLA) for daratumumab with U.S. FDA for the Treatment of Multiple Myeloma, News Release, 3 pages (2015).Applicant
• Janssen to Demonstrate Breadth of Oncology Portfolio with 41 Clinical Data Presentations at the 2014 American Society of Hematology (ASH) Annual Meeting [online], Nov. 6, 2014, Internet:<URL: https://www.jnj.com/media-center/press-releases/janssen-to-demonstrate-breadth-of-oncology-portfolio-with-41-clinical-data-presentations-at-the-2014-american-society-of-hematology-ash-annual-meeting>; 8 pages.Applicant
• Janssen Submits Marketing Authorisation Application for Daratumumab for European Patients with Heavily Pre-treated Multiple Myeloma, Janssen-Cilag International NV; 7 pages (2015).Applicant
• Johnson, et al., “Primary plasma cell leukemia: morphologic, immunophenotypic , and cytogenetic features of 4 cases treated with chemotherapy and stem cell transplantation,” Annals of Diagnostic Pathology, 10: 263-268 (2006).Applicant
• Johnson & Johnson, Janssen to Demonstrate Breadth of Oncology Portfolio with 42 Clinical Data Presentation at the 2014 American Society of Hematology (ASH) Annual Meeting, San Francisco, California (Nov. 2014).Applicant
• Jolles, S., “Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency,” Immuno Targets and Therapy, vol. 2; 125-133 (2013).Applicant
• Jones, et al., “Depletion of CD25+ regulatory calls results in suppression of melanoma growth and induction of autoreactivity in mice,” Cancer Immunity, 2: 1 (2002). Abstract.Applicant
• Jones, et al., “Replacing the complementarity-determining regions in a human antibody with those from a mouse,” Nature, 321: 522-525 (1986).Applicant
• Kang, W. et al., “Inference of synergy/antagonism between anticancer drugs from the pooled analysis of clinical trials,” BMC Medical Research Methodology, vol. 13; No. 77; 8 pages (2013).Applicant
• Karakasheva et al., “CD38-Expressing Myeloid-Derived Suppressor Cells Promote Tumor Growth in a Murine Model of Esophageal Cancer”, Microenvironment and Immunol., 75(19), pp. 4074-4085, Oct. 1, 2015.Applicant
• Kaufman, J.L. et al., “Bortezomib, Thalidomide, and Dexamethasone as Induction Therapy for Patients with Symptomatic Multiple Myeloma,” Cancer, vol. 116; 3143-3151 (2010).Applicant
• Kaufman, G.P. et al., “Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis,” Blood, vol. 130; No. 7; 900-902 (2017).Applicant
• Khagi, Y. and Mark, T., “Potential role of daratumumab in the treatment of multiple myeloma,” Onco Targets and Therapy, 1095-1100 (2014).Applicant
• Khan, T. and Salunke, D.M., “Adjustable Locks and Flexible Keys: Plasticity of Epitope-Paratope Interactions in Germline Antibodies,” The Journal of Immunology, vol. 192; 5398-5405 (2014).Applicant
• Kim, H. et al., “Overview of methods for comparing the efficacies of drugs in the absence of head-to-head clinical trial data,” Br. J. Clin. Pharmacol., vol. 77; No. 1; 116-121 (2013).Applicant
• King, T. et al., “Best Practice for the Administration of Daratumumab in Multiple Myeloma: Australian Myeloma Nurse Expert Opinion,” Asia Pac J Oncol Nurs, vol. 5; 270-284 (2018).Applicant
• Kita et al., “Antitumor effects of YM155, a novel suppressant, against human aggressive non-Hodgkin Lymphoma,” Leukemia Research, vol. 35, pp. 787-792, (2011).Applicant
• Kita, A., et al., “Sepantronium Bromide (YM155) Enhances Response of Human B-Cell Non-Hodgkin Lymphoma to Rituximab,” The Journal of Pharmacology and Experimental Therapeutics, vol. 343; No. 1; 178-183 (2012).Applicant
• Knowles, S.P. et al., “Safety of recombinant human hyaluronidase PH20 for subcutaneous drug delivery,” Expert Opinion on Drug Delivery, vol. 18; No. 11; 1673-1685 (2021).Applicant
• Konapleva, et al., “Ligation of Cell Surface CD38 Protein with Agonistic Monoclonal Antibody Induced a Cell Growth Signal in Myeloid Leukemia Cells,” The Journal of Immunology, 161: 4702-4708 (1998).Applicant
• Kong, S.Y., et al., “Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs,” Blood, vol. 116; Abstract 3013 (2010).Applicant
• Konopleva, et al., “CD38 in Hematopoietic Malignancies,” Chemical Immunol. Basel Karger, 75: 189-206 (2000).Applicant
• Kreitman, et al., Phase I Trial of Recombinant Immunotoxin Anti-Tac (Fv)-PE38 (LMB-2) in Patients with Hematologic Malignancies, Journal of Clinical Oncology, 18: 1622-1636 (2000).Applicant
• Krejcik, J. et al., “Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma,” Blood, vol. 128; No. 3; 384-394 (2016).Applicant
• Krejcik, J. et al., Immunomodulatory Effects and Adaptive Immune Response to Daratumumab in Multiple Myeloma,: Blood, vol. 126; 3037; 7 pages (2015).Applicant
• Kreuger, et al., “Successful in vivo blockade of CD25 (high-affinity interleukin 2 receptor) on T cells by administration of humanized anti-Tac antibody to patients with psoriasis,” Journal of American Academy of Dermatology, 41(3): 448-458 (2000).Applicant
• Kropff, et al., “Bortezomib in combination with dexamethoasone for relapsed multiple myeloma,” Leukemia Research, 29: 587-590 (2005).Applicant
• Kumar, S. et al., “Expression of CD52 on plasma cells in plasma cell proliferative disorders,” Blood, vol. 102; No. 3; 1075-1077 (2003).Applicant
• Kupiec-Weglinski, “CD25-Targeted Therapy Revisited,” Transplantation, 69(3): 328-330 (2000).Applicant
• Kussie, P.H. et al., “A Single Engineered Amino Acid Substitution Changes Antibody Fine Specificity,” Journal of Immunology, vol. 152; 146-152 (1994).Applicant
• Kwan et al., “Complement regulation of T cell immunity”, Immunol Res, 54(0), pp. 247-253, Dec. 2012.Applicant
• Kyle, R.A. and Rajkumar, S.V., “Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma,” Leukemia, vol. 23; 3-9 (2009).Applicant
• Kyle, R.A. et al., “Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma,” The New England Journal of Medicine, vol. 356; 2582-2590 (2007).Applicant
• Kyle, R.A. et al., “Review of 1027 Patients with Newly Diagnosed Multiple Myeloma,” May Clinic Proc., vol. 78; 21-33 (2003).Applicant
• Lakshman, A. et al., “Efficacy of daratumumab-based therapies in patients with relapsed, refractory multiple myeloma treated outside of clinical trials,” Am J. Hematol., vol. 92; 1146-1155 (2017).Applicant
• Lande, et al., “CD38 ligation plays a direct role in the induction of IL-1β, I-6, and IL-10 secretion in resting human monocytes,” Cellular Immunology, 220: 30-38 (2002).Applicant
• Laubach, J.P., “Daratumumab granted breakthrough drug status,” Expert Opinion Investig. Drugs, vol. 23; No. 4; 445-452 (2014).Applicant
• Laubach, J.P. et al., “The challenge of cross-trial comparisons using limited data,” haematologica, vol. 99; e145; 2 pages (2014).Applicant
• Laurie, et al., “The role of CD4+CD25+ immunoregulatory T cells in the induction of autoimmune gastritis,” Immunology and Cell Biology, 80: 567-573 (2002).Applicant
• Laurini, J.A. et al., “Classification of non-Hodgkin lymphoma in Central and South America: a review of 1028 cases,” Blood, vol. 120; vol. 24; 4795-4801 (2012).Applicant
• Lazar, et al., “Transforming Growth Factor a: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities,” Molecular and Cellular Biology, 8(3): 1247-1252 (1988).Applicant
• Lefranc, M. et al., “IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains,” Developmental & Comparative Immunology, vol. 27; 55-77 (2003).Applicant
• Leonard, et al., “Molecular cloning and expression of cDNAs for the human interleukin-2 receptor,” Nature 311(18): 626-631 (1984).Applicant
• Lepenies, B. and Jacobs, T., “The Role of Negative Costimulators During Parasitic Infections,” Endocrine, Metabolic & Immune Disorders—Drug Targets, vol. 8; 279-288 (2008).Applicant
• Leukemia—Acute Myeloid—AML—Treatment Options. Cancer.Net, Nov. 19, 2013. archived by the Wayback Machine at https://web.archive.org/web/20131120003806/http://www.cancer.net/print/19072; Retrieved on Nov. 20, 2023; 6 pages (No Author Listed).Applicant
• Leveque “Subcutaneous Administration of Anticancer Agents” Anticancer Research, Departments of Pharmacy, University Hospital, Strasbourg, France, vol. 34, pp. 1579-1586 (2014).Applicant
• Li, et al., “Creation of Patient Derived AML Xenografts Displaying Distinct Phenotypes and Geneotypes,” Blood, vol. 122: No. 21, p. 5018 (2013).Applicant
• Lin, et al., “Structure-Function Relationships in Glucagon: Properties of Highly Purified Des-His1-, Monoiodi-, and [Des-Asn28, Thr29](homoserine lactone27)-glucagon,” Biochemistry, 14(9): 1559-1563 (1975).Applicant
• Lippincott-Schwartz, “Antibodies as cell Biological Tools,” Current Protocols in Cell Biology, 16.0.1-16.0.2, (2002).Applicant
• Liu et al., “Induction of Chemoresistance by All-Trans Retinoic Acid via a Noncanonical Signaling in Multiple Myeloma Cells,” PLOS One, vol. 9, No. 1, page Article No. e85571, Jan. 2014.Applicant
• Lokhorst, H.M. et al., “Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma,” The New England Journal of Medicine, vol. 373; 1207-1219 (2015).Applicant
• Lokhorst, H.M. et al., “Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma,” The New England Journal of Medicine, vol. 373; 1207-1219 (2015); Supplemental Appendix.Applicant
• Lonberg, et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature: 308: 856-859 (1994).Applicant
• Lonial, S. et al., “Phase II study of daratumumab (DARA) monotherapy in patients with greater than or equal to 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius),” Journal of Clinical Oncology, vol. 33; No. 18_Suppl (2015).Applicant
• Lonial, S. et al., “Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives,” Leukemia, vol. 30; 526-535 (2016).Applicant
• Lu et al., “Issues Related to Targeted Delivery of Proteins & Peptides,” The AAPS Journal, vol. 8, No. 3, Article 55, pp. E466-E478, Jul. 21, 2006.Applicant
• MacCallum, et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography,” Journal of Molecular Biology, 262, 732-745 (1998).Applicant
• Machida, H. et al., “Aggressive plasma cell leukemia with cleaved, multilobated and monocytoid nuclei,” International Journal of Hematol., vol. 73; Suppl 1; 158; Abstract No. 411 (2001). (concise explanation met by submission of the enclosed English Translation of a Foreign Office Action cited as Other Document 400).Applicant
• Mahajan, S. et al., “The evolution of stem-cell transplantation in multiple myeloma,” Therapeutic Advances in Hematology, vol. 9; No. 5; 123-133 (2018).Applicant
• Mai, E. et al., “Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (Pad) in newly diagnosed myeloma,” Leukemia, vol. 29; 1721-1729 (2015).Applicant
• Malavasi, et al., “Human CD38: a glycoprotein in search of a function,” Immunology Today, 15(3): 95-97 (1994).Applicant
• Maloney, et al., “Antibody Therapy for Treatment of Multiple Myeloma,” Semin Hematol. 36 (Suppl. 3): 30-33 (1999).Applicant
• Manier, S. et al., “Bone Marrow Microenvironment in Multiple Myeloma Progession,” Journal of Biomedicine and Biotechnology, vol. 2012; 5 pages (2012).Applicant
• Mariuzza, R.A. eet al., “The Structural Basis of Antigen-Antibody Recognition,” Ann. Rev. Biophys. Biophys. Chem., vol. 16; 139-159 (1987).Applicant
• Matas-Cespedes, A. et al., “The human CD38 monoclonal antibody daratumumab shows anti-tumor activity and hampers leukemia-microenvironment interactions in chronic lympocytic leukemia,” Clinical Cancer Research, vol. 23; No. 6; 1493-1505 (2017).Applicant
• Mateos, M. et al., “Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma,” N England J Med, vol. 378; 518-528 (2018).Applicant
• Matsuda, M. et al., “Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis,” Amyloid, 10(2), 110-116 (2003).Applicant
• Mauri, C. and Menon, M., “The expanding family of regulatory B cells,” International Immunology, vol. 27; No. 10; 479-486 (2015).Applicant
• Maury, M. et al., “Spray-drying of proteins: effects of sorbitol and trehalose on aggregation and FT-IR amide I spectrum of an immunoglobulin G,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 59; 251-261 (2005).Applicant
• McCarthy, P.L., “Strategies for induction, autologous hematopoietic stem cell transplantation, consolidation, and maintenance for transplantation-eligible multiple myeloma patients”, Hematology, vol. 2013, NI. 1, pp. 496-503 (Dec. 2013).Applicant
• McCudden, C. et al., “Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference,” Clin Chem Lab Med, vol. 54; No. 6; 1095-1104 (2016).Applicant
• McKelvey, et al., “Hydroxyldaunomycian (Adriamycin) Combination Chemotherapy in Malignant Lymphoma,” Cancer, vol. 38, No. 4, pp. 1485-1493 (Oct. 1976).Applicant
• McLaughlin, P. et al., “Pituximab Chimeric Anti-CD20 Monoclonal Antibody Therapy for Relapsed Indolent Lymphoma: Half of Patients Respond to a Four-Dose Treatment Program,” Journal of Clinical Oncology, vol. 16; No. 8; 2825-2833 (1998).Applicant
• Merlini, G. and Bellotti, V., “Molecular Mechanisms of Amyloidosis,” The New England Journal of Medicine, vol. 349; No. 6; 583-596 (2003).Applicant
• Mikhael et al., “Cyclophosphamide-Bortezomib-Dexamethasone (CYBORD) Produces Rapid and Complete Hematological Response in Patients with AL Amyloidosis,” Blood 119:4391-94 (Year: 2012).Applicant
• Mills, et al., Characterization of Monoclonal Antibodies that Inhibit CD38 ADp-ribosyl Cyclase Activity, LSSURP HLB Program, Department of Pharmacology, University of Minnesota, 2007.Applicant
• Mills, E.N.C et al., “The prevalence, cost and basis of food allergy across Europe,” Allergy, vol. 62; 717-722 (2007).Applicant
• Mohammad et al., “The Addition of Bryostatin 1 to Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) Chemotherapy Improves Response in a CHOP-resistant Human Diffuse Large Cell Lymphoma Xenograft Model,” Clinical Cancer Research, vol. 6, 4950-4956 (Dec. 2000).Applicant
• Moreau, P. et al., “Rituximab in CD20 positive multiple myeloma,” Leukemia, vol. 21; 835-836 (2007).Applicant
• Moreau, P. et al., “Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma,” Drugs, vol. 76; 853-867 (2016).Applicant
• Moreau, P. et al., “Multiple Myeloma: ESMO Clinical Practice Guidelines for dianosis, treatment and follow up,” Annals of Oncology, vol. 28; Suppl 4; iv52-iv61 (2017).Applicant
• Morris, G.E., “Epitope Mapping of Protein Antigens by Competition ELISA,” In: Walker, J.M. (eds) The Protein Protocols Handbook. Springer Protocols Handbooks. Humana Press; 595-600 (1996).Applicant
• Morrison, et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains,” Proceedings of the National Academy of Science USA, vol. 81; 6851-6855 (1984).Applicant
• Mrowietz, “Treatment of Severe Psoriasis with Anti-CD25 Monoclonal Antibodies,” Arch. Dermatology, 136: 675-676 (2000).Applicant
• Mukherjee, et al., “Production and Characterization of Protective Human Antibodies against Shiga Toxin 1,” Infection and Immunity, 70(10): 5896-5899 (2012).Applicant
• Multiple Myeloma Treatment Regiments (MMTR), Multiple Myeloma Treatment Regiments (Part 1 of 9), Haymarket Media, Inc., 9 Pages (2017).Applicant
• Muyldermans, “Single domain camel antibodies: current status,” Reviews in molecular Biotechnology, 74: 277-302 (2001).Applicant
• Muyldermans, et al., “Recognition of antigens by single-domain antibody fragments: the superfluous luxury of paired domains,” Trends in Biochemical Sciences, 26(4): 230-235 (2001).Applicant
• Myeloma Australia, “Steroids,” Treatment Fact Sheet, Myeloma Australia, retrieved from: https://myeloma.org.au/wp-content/uploads/2018/09/Steroid-FS-Sep18.pdf 2 Pages (2018).Applicant
• Nahi, H. et al., “An open-label, dose escalation phase 1b study of subcutaneous daratumumab with recombinant human hyaluronidase in patients with relapsed or refractory multiple myeloma (PAVO),” Journal of Clinical Oncology, vol. 34; No. 15; 4 pages (2016).Applicant
• Najjar et al., “Abstract P227: Accumulation of MDSC Subsets in Renal Cell Carcinoma Correlates with Grade and Progression Free Survival, and is Associated with Intratumoral Expression of IL-1β, IL-8 and CXCL5,” Journal for Immunotherapy of Cancer, Nov. 6, 2014, vol. 2, p. 110-112.Applicant
• Negrin, R., Patient education: Hematopoietic transplantation (bone marrow transplantation) (Beyond the Basics), Retrieved from Internet URL: https://www.uptodate.com/contents/hematopoietic-cell-transplantation-bone-marrow-transplantation-beyond-the-basics, 15 pages; Retrieved on Oct. 27, 2022.Applicant
• Nijhof, I.S. et al., Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib. Clin Cancer Res., vol. 21, No. 12, pp. 2802-2810 (2014).Applicant
• Nijhof, et al., “Modulation of CD 38 Expression Levels on Multiple Myeloma Tumor Cells by All-Trans Retinoic Acid Improves the Efficacy of the Anti-CD 38 Monoclonal Antibody Daratumumab,” Blood, American Society of Hematology, US, vol. 124, No. 21, p. 2096, Dec. 6, 2014. (Abstract Only).Applicant
• Nijhof, I.S. et al., Combination of the anti-CD38 monoclonal antibody daratumumab and all-trans retinoic acid (Abstract in Proceedings of the AACR Special Conference on Hematologic Malignancies: Translating Discoveries to Novel Therapies). Clin Cancer Res, Sep. 20, 2014, vol. 21, No. 17 Suppl, pp. Abstract A12; Abstract.Applicant
• Nijhof I.S. et al.: “Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab”, Leukemia, vol. 29, No. 10, ISSN 1476-5551, pp. 2039-2049 (2015).Applicant
• Nikaido, et al., “Molecular cloning of cDNA encoding human interleukin-2 receptor,” Nature, 311: 631-635 (1984).Applicant
• Ocio, E.M. et al., “New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG),” Leukemia, vol. 28; 525-542 (2014).Applicant
• Offidani et al., “An evidence-based review of ixazomib citrate and its potential in the treatment of newly diagnosed multiple myeloma,” OncoTargets and Therapy, vol. 7, pp. 1793-1800, 2014.Applicant
• Ohaegbulam K C et al.: “Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway”, Trends in Molecular Medicine, Jan. 2015; 21 (1): 24-33.Applicant
• Onizuka, et al., “Tumor Rejection by in Vivo Administration of Anti-CD25 (Interleukin-2 Receptor α Monoclonal Antibody,” Cancer Research, 59: 3128-3133 (1999).Applicant
• Orlowski, “The Ubiquitin Proteasome pathway from Bench to Bedside,” American Society of Hematology, 220-225 (2005).Applicant
• Ortolani, C., “CD38: Antigen: Flow Cytometry of Hematological Malignancies,” Blackwell Publishing, 1st Edition, 68-70 (2011).Applicant
• Ostberg, et al., “Human and humanized monoclonal antibodies: preclinical studies and clinical experience,” Biochemical Society Transactions, 23: 1-6 (1995).Applicant
• Padlan, et al., “Identification of specificity-determining resides in antibodies,” FASEB Journal, 9: 135-139 (1995).Applicant
• Palumbo, A. et al., “International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation,” Leukemia, vol. 23; 1716-1730 (2009).Applicant
• Palumbo, A. and Anderson, K., “Multiple Myeloma,” The New England Journal of Medicine, vol. 364; 1046-1060 (2011).Applicant
• Palumbo, A. et al., “Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma,” The New England Journal of Medicine, vol. 375; No. 8; 754-766 (2016).Applicant
• Palumbo, A. et al., “Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma,” The New England Journal of Medicine, vol. 375; No. 8; 754-766; Suppl. Material: the protocol; total pp. 119 (2016).Applicant
• Panka, D.J. et al., “Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies,” Proc. Natl. Acad. Sci., vol. 85, 3080-3084 (1988).Applicant
• Park, S. et al., “Successful Treatment by Rituximab of an Ebv-Related Lymphoma after Autologous Transplantation for Angioimmunoblastic T-Cell Lymphoma,” International Journal of Hematol., vol. 76; Suppl. 1; 118; Abstract No. P340 (2002).Applicant
• Parren et al., “HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells,” American Society of Hematology 47th annual meeting, Atlanta, Georgia, USA, Dec. 10-13, 2005 (Abstract).Applicant
• Parren, et al., HuMax-CD38, Myconos, Jun. 26, 2006.Applicant
• Parren, et al., HuMax-CD38, Torino, Jun. 8-10, 2006.Applicant
• Pascual, et al., “Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab,” Nephrology Dial. Transplant, 16: 1756-1760 (2001).Applicant
• Patel, J.P., “Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia,” The New England Journal of Medicine, vol. 366; No. 12; 1079-1089 (2012).Applicant
• Patent Assignment Cover Sheet for U.S. Appl. No. 16/380,994, 6 pages; Sep. 11, 2019.Applicant
• Patton, D.T. et al., “The P13K p110δ Regulates Expression of CD38 on Regulatory T Cells,” PLOS one, vol. 6; No. 3; e17359; 8 pages (2011).Applicant
• Paul, M.D., “Fundamental Immunology,” Chapter 9, Raven Press, New York, 3rd ed., 292-295 (1993).Applicant
• Peipp, et al., “Fully Human CD38 Antibodies Efficiently Trigger ADCC and CDC of Multiple Myeloma Cell Lines and Primary Tumor Cells (Poster),” Blood, vol. 106(11): 944A, 47th Annual Meeting of the American Society of Hematology, 2005; published (Nov. 16, 2005).Applicant
• Peipp, et al., Fully Human CD38 Antibodies Efficiently Trigger ADCC and CDC of Multiple Myeloma and Plasma Cell Leukemia Cells (Poster 2) Conference proceedings, poster presentation at the 2005 Annual Meeting of the American Society of Hematology, (Dec. 12, 2005).Applicant
• Peipp, et al., 47th Annual Meeting of the American Society of Hematology, Atlanta, GA, Dec. 10-13, 2005. (Meeting Abstract).Applicant
• Peng, et al., “Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker,” Blood, 101, 2557-2562 (2003).Applicant
• Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients With Selected CD38+ Hematological Malignancies, First posted Mar. 10, 2010, ClinicalTrials.gov. identifier No. NCT01084252.Applicant
• Phase 3 Columbia study Investigating a Subcutaneous Formulation of Darzalex (daratumumab) Showed Non-Inferiority to Intravenous Administration in Patients with Relapsed/Refractory Multiple Myeloma, Chicago, 7 pages (2019).Applicant
• Phipps, C., et al., “Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development,” Ther. Adv. Hematol., vol. 6; No. 3; 120-127 (2015).Applicant
• Piro, L.D. et al., “Extended Rituximab )anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkins lymphoma,” Annals of Oncology, vol. 10; 655-661 (1999).Applicant
• Pivot, X. et al., “Patients' preferences for subcutaneous trastuzumab versus conventional intravenous infusion for the adjuvant treatment of HER2-positive early breast cancer: final analysis of 488 patients in the international, randomized, two-cohort PrefHer study,” Annals of Oncology, vol. 25; 1979-1987 (2014).Applicant
• Poosarla, V.G. et al., “Computational De Novo Design of Antibodies Binding to a Peptide With High Affinity,” Biotechnology & Bioengineering, vol. 114; No. 6; 1331-1342 (2017).Applicant
• Pre-Grant Notice of Opposition filed in Indian Application No. 201617029109, by Indian Pharmaceutical Alliance, dated Feb. 24, 2022 (30 pages).Applicant
• Preliminary Opinion of the Opposition Division, as cited in EP Opposition against EP Patent No. 3370770; 13 pages; dated Aug. 8, 2022.Applicant
• Prosniak, M. et al.: “Development of a Cocktail of Recombinant-Expressed Human Rabies Virus-Neutralizing Monoclonal Antibodies for Postexposure Prophylaxis of Rabies,” The Journal of Infectious Diseases, vol. 187; 53-56 (2003).Applicant
• Pui, C. and Jeha, S., “New therapeutic strategies for the treatment of acute lymphoblastic leukemia,” Nature Reviews, vol. 6; 149-165 (2007).Applicant
• Rader, C. et al., “A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries,” Proc. Natl. Acad. Sci, vol. 95; 8910-8915 (1998).Applicant
• Rai, S. et al., “Successful Allogeneic Hematopoietic Stem Cell Transplantation in a Young Patient with Richter Syndrome Presenting with Chronic Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma with Different Cell Origins,” Intern Med, vol. 52; 273-276 (2013).Applicant
• Raj, T.A. et al., “Vincristine sulfate liposomal injection for acute lymphoblastic leukemia,” International Journal of Nanomedicine, vol. 8; 4361-4369 (2013).Applicant
• Rajkumar, S.V. et al., “Consensus recommendations for the uniform reporting of clinical trials: Report of the International Myeloma Workshop Consensus Panel 1,” Blood, vol. 117; No. 18; 4691-4695 (2011).Applicant
• Richardson, et al., “Daratumumab,” Drugs of the Future, 38(8): 545-554 (2013).Applicant
• Rituxan Hycela Label, “Highlights of prescribing information. Rituxan Hycela™ (rituximab and hyaluronidase human) injection, for subcutaneous use,” 32 pages (Jun. 2017).Applicant
• Rituxan (tituximab), Highlights of prescribing information. Rituxan (IV administered Rituximab; 35 pages (1997).Applicant
• Rituxan (tituximab), Highlights of prescribing information. Rituxan (IV administered Rituximab; 44 pages (1997); Revised 2014.Applicant
• Rosengren, S. et al., Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration, The AAPS Journal, vol. 17; No. 5; 1144-1156 (2015).Applicant
• Ruberg, E-M. and FrieB, W., “Sensibel und stressanfallig,” Pharmazeutische Zeitung, 156 JG, AUSG. 50; 15 pages (2011). (concise explanation met by submission of the enclosed Notice of Opposition filed by Dr. Markus Breuer cited as Other Document 404).Applicant
• Rudikoff, S. et al., “Single amino acid substitution altering antigen-binding specificity,” Proc. Natl. Acad., col. 79; 1979-1983 (1982).Applicant
• Ryan, et al., “Potentiation of Anti-Myeloma Activity of Daratumumab with Combination of Cyclophosphamide, Lenalidomide or Bortezomib via a Tumor Secretory Response That Greatly Augments Macrophage-Induced ADCP,” Annual Meeting at the Haematology Association of Ireland, Oct. 15, 2016; 20 pages.Applicant
• Sachchithanantham, S. et al., “Use of Plasma Cell Immunophenotype as Prognostic Markers in Patients with Systemic AL Amyloidosis,” Blood, vol. 122; p. 3120 (2013).Applicant
• Sagaster, V. et al., “Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion,” Leukemia, vol. 21; 164-168 (2007).Applicant
• Saito, M. et al., “A Case of Retroperitoneal Extramedullary Plasmacytoma,” Acta Urol. Jpn., vol. 49; 735-739 (2003).—English Abstract attached.Applicant
• Salar et al., “Comparison of Subcutaneous Versus Intravenous Administration of Rituximab as Maintenance Treatment for Follicular Lymphoma: Results From a Two-Stage, Phase IB Study,” Journal of Clinical Oncology, vol. 32, No. 17, pp. 1782-1791, (Jul. 10, 2014).Applicant
• Sanchez-Gonzalez et al., “Rituximab subcutaneous in B-Cell non-Hodgkin lymphoma: clinical experience in a single center,” Leukemia & Lymphoma, vol. 59, No. 4, pp. 1019-1021 (2018).Applicant
• San-Miguel, J. et al., “Efficacy by cytogenetic risk status for daratumumab in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone in relapsed or refractory multiple myeloma,” EHA22; EHA Learning Center; Abstract; 3 pages (2017).Applicant
• San-Miguel, J., et al., “Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Update of the Open-label, Multicenter, Dose Escalation Phase 1b Study (PAVO)”, Poster Presented at the 23rd European Hematology Association (EHA) Annual Congress; Jun. 14-17, 2018; Stockholm, Sweden.Applicant
• San-Miguel, J., “New approaches to myeloma treatment in 2017,” EHA Learning Center; Abstract; 4 pages (2017).Applicant
• Schonland, S., et al., “Detection and Charaterization of Plasma Cell and B Cell Clones in Patients with Systemic Light Chain Amyloidosis Using Flow Cytometry,” Blood, vol. 142, p. 2068 (2014).Applicant
• Sher, T. et al., “First report of safety and efficacy of daratumumab in 2 cases of advanced immunoglobulin light chain amyloidosis,” Blood, vol. 128; No. 15; 1987-1989 (2016).Applicant
• Shields, et al., “High Resolution mapping of the binding site on human IgG1 for FcγRi, FcγRII, FcγRIII, and FcRn and design of IgGI variants with improved binding to the FcγR,” J. Biol. Chem., vol. 276, No. 9, pp. 6591-6604, (2001).Applicant
• Shpilberg, et al., “Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase,” British Journal of Cancer, vol. 109, pp. 1556-1561, 2013.Applicant
• Shubinsky, et al., “The CD38 Lymphocyte Differentiation Marker: New Insight into Its Ectoenzymatic Activity and Its Role as a Signal Transducer,” Immunity, 7: 315-324 (1997).Applicant
• Sicherer, S.H. and Sampson, H.A., “Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment,” J. Allergy Clin Inmmunol, vol. 133; 291-307 (2014).Applicant
• Skeel, Handbook of Cancer Gliemotherapy, 3rd edition, Little, Brown & Co., pp. 330-350 (1991).Applicant
• Smithson, G. et al., “TAK-079 is a high affinity monoclonal antibody that effectively mediates CD38+ cell depletion,” Journal of Immunol., vol. 198; Suppl. 1; 224.20; Abstract (2017).Applicant
• Solal-Deligny, P., “Rituximab by subcutaneous route,” Expert Rev. Hematol., vol. 8; No. 2; 147-153 (2015).Applicant
• Sondergeld, P. et al., “Monclonal Antibodies in Myeloma,” Clinical Advances in Hematology & Oncology, vol. 13; Issue 9; 599-609 (2015).Applicant
• Sonneveld, P. and Annemiek Broijl, “Treatment of Relapsed and Refractory Multiple Myeloma,” Review Article, Leaders in Hematology, review series, Haematologica, 101(4):396-406 (2016).Applicant
• Spencer, A. et al., “Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of Castor,” Haematologica, vol. 103; No. 12; 2079-2087 (2018).Applicant
• Strickley, R.G. and Lambert, W.J., “A review of formulations of commercially available antibodies,” Journal of Pharmaceutical Sciences, vol. 110; 2590-2608 (2021).Applicant
• Strome, S.E. et al., “A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects,” The Oncologist, vol. 12; 1084-1095 (2007).Applicant
• Swaika, A. et al., “Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy,” Molecular Immunology, vol. 67; 4-17 (2015).Applicant
• Tabernero, et al., “Adult precursor B-ALL with BCR/ABL gene rearrangements displays a unique immunophenotype based on the pattern of CD10, CD34, CD13, and CD38 expression,” Leukemia, vol. 15, No. 3, pp. 406-414, (2001).Applicant
• Talmadge, J.E. and Gabrilovich, D.I, “History of myeloid-derived suppressor cells,” Nature Reviews, vol. 13; 739-752 (2013).Applicant
• Taussig, D.C. et al., “Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells,” Blood, vol. 112; No. 3; 568-575 (2008).Applicant
• Terhorst, et al., “Biochemical Studies of the Human Thymocyte Cell-Surface Antigens T6, T9 and T10,” Cell, 23: 771-780 (1981).Applicant
• The Cancer Genome Atlas Research Network et al., “Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia,” N. Engl. J. Med, vol. 368; No. 22; 2059-2074 (2013).Applicant
• Thomas, D.A. et al., “Chemoimmunotherapy with Hyper-CVAD plus Rituximab for the Treatment of Adult Burkitt and Burkitt-Type Lymphoma or Acute Lymphoblastic Leukemia,” The American Cancer Society, vol. 106; No. 7; 1569-1580 (2006).Applicant
• Topalian, S.L., et al., “Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy,” Cancer Cell, vol. 27; 450-461 (2015).Applicant
• Tzartos, S.J., et al., “Epitope Mapping by Antibody Competition,” Methods in Molecular Biology, vol. 66; 55-66 (1996).Applicant
• Usmani, et al., “Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma,” Blood, vol. 128, No. 1, pp. 37-44, (May 23, 2016).Applicant
• Usmani, S.Z. et al., “Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux,” Blood, vol. 128; No. 22; 1151; 10 pages (2016).Applicant
• Usmani, S.Z. et al., “Open-Label, Multicenter, Dose Escalation Phase 1b Study to Assess the Subcutaneous Delivery of Daratumumab in Patients (pts) with Relapsed or Refractory Multiple Myeloma,” Blood, vol. 128; No. 22; 1149 (2016).Applicant
• Usmani, S.Z. et al., “Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma,” Blood, vol. 134; No. 8; 668-677 (2019).Applicant
• Usmani, S.Z. et al., “Final analysis of the phase III non-inferiority Columba study of subcutaneous versus intravenous daratumumab in patients with relapsed or refractory multiple myeloma,” Haematologica, vol. 107; 2408-2417 (2022).Applicant
• Vadjos, et al., “Comprehensive Functional Maps of the Antigen-binding Site of an Anti-ErbB2 Antibody Obtained with Shotgun Scanning Mutagenesis,” Journal of Molecular Biology, 320: 415-428 (2002).Applicant
• Van Bueren, et al., “Direct In Vitro Comparison of Daratumumab With Surrogate Analogs of Anti-CD38 Antibodies,” New Evidence Oncology Issue, Apr. 2015 [retrieved on Feb. 3, 2016] Retrieved from the Internet: URL: Http:///www.newevidence.com/oncology/direct-in-vitro-comparison-of-daratumumab-with-surrogate-analogs-of-anti-cd38-antibodies>.Applicant
• Van Beurden-Tan et al., “Systemic Literature Review and Network Meta-Analysis of Treatment Outcomes in Relapsed and/or Refractory Multiple Myeloma,” Journal of Clinical Oncology, vol. 35; No. 12; 1312-1319 (2017).Applicant
• Van de Donk et al., “Monoclonal antibodies targeting CD38 in hematological malignancies and beyond,” Immunological Reviews, vol. 270, pp. 95-112, (2016).Applicant
• Venner et al., “Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival,” Blood, vol. 119, No. 9, pp. 4387-4390, (2012).Applicant
• Vorre, et al., “Multiple Daratumumab Abstracts to be Presented at EHA,” ArrayDiagnostica, Abstract Only (2014).Applicant
• Wagner, V., et al., “Preclinical Efficacy of Sepantronium Bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1,” Oncotarget, 5(21): 10237-10250 (2014).Applicant
• Wagner et al., Survivin in Multiple Myeloma: Prognostic and Therapeutic Implications, vol. 118, Article 137, 2011 (Abstract Only).Applicant
• Wang, W. et al., “Antibody Structure, Instability, and Formulation,” Journal of Pharmaceutical Sciences, vol. 96; 1-26 (2007).Applicant
• Wang, L. et al., “VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses,” J. Exp. Med., vol. 208; No. 3; 577-592 (2011).Applicant
• Warne, N.W., “Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 78; 208-212 (2011).Applicant
• Wasserman, R.L., “Progress in Gammaglobulin Therapy for Immunodeficiency: From Subcutaneous to Intravenous Infusions and Back Again,” J. Clin. Immunol., vol. 32 ;1153-1164 (2012).Applicant
• Wasserman, R.L., “Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies,” Immunotherapy, vol. 6; No. 5; 553-567 (2014).Applicant
• WCJ van de Donk, “A Phase 1 and Phase 2 Study of Daratumumab in Combination With All-Trans Retinoic Acid in Relapsed/Refractory Multiple Myeloma,” Clinical Trials.gov Identification No. NCT02751255; (First posted Apr. 26, 2016).Applicant
• Wei, W. et al., “Roles and mechanisms of the CD38/cyclic adenosine diphosphate ribose/Ca2+ signaling pathway,” World Journal of Biological Chemistry, vol. 5; No. 1; 58-67 (2014).Applicant
• Weisel, K.C. et al., “Efficacy of daratumumab in combination with lenalidomide plus dexamethasone (DRd) or bortezomib plus dexamethasone (RVd) in relapsed or refractory multiple myeloma (RRMM) based on cytogenetic risk status,” Journal of Clinical Oncology, vol. 35; No. 15; 8006; Abstract (2017).Applicant
• Whatcott et al., “Targeting the tumor microenvironment in cancer: why hyaluronidase deserves a second look”, Cancer Discov., 1(4), pp. 291-296, Sep. 2011.Applicant
• WHO Drug Information, International Nonproprietary Names for Pharmaceutical Substances (INN), Proposed INN: List 101, vol. 23; No. 2; 64 pages (2009).Applicant
• WHO Drug Information, International Nonproprietary Names for Pharmaceutical Substances (INN), Recommended INN: List 63, 40 pages (2010).Applicant
• Wu, et al., An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and Their Implications for Antibody Complementarity, Journal of Experimental Medicine, 132: 211-250 (1970).Applicant
• Wunderlich, M. et al., “AML cells are differentially sensitive to chemotherapy treatment in a human xenograft model,” eBlood, vol. 121; No. 12; e90-e97 (2013).Applicant
• Yamamoto, H. et al., “A mammalian homolog of the zebrafish transmembrane protein 2 (TMEM2) is the long-sought-after cell-surface hyaluronidase,” J. Biol. Chem., vol. 292; No. 18; 7304-7313 (2017).Applicant
• Ye et al., “Abstract P240: Treg Increases HepG2 Cell Growth by RANK-RANKL pathway.” Journal for Immunotherapy of Cancer, vol. 2; Suppl 3; p. 240 (Nov. 6, 2014).Applicant
• Zadnikova, P. et al., “The Degradation of Hyaluronan in the skin,” Biomolecules, vol. 12; 251, 17 pages (2022).Applicant
• Zagouri, F. et al., “Emerging antibodies for the treatment of multiple myeloma,” Expert Opinion on Emerging Drugs, vol. 21; No. 2; 225-237 (2016).Applicant
• Zojer, N. et al., “Rituximab treatment provides no clinical benefit in patients with pretreated advanced multiple myeloma,” Leukemia & Lymphoma, vol. 47; No. 6; 1103-1109 (2006).Applicant
• International Preliminary Report on Patentability issued May 8, 2018 for International Application No. PCT/US2016/59893, entitled “Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses”.Applicant
• International Search Report and Written Opinion mailed Jan. 24, 2017 for International Application No. PCT/US2016/59893, entitled “Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses”.Applicant
• International Preliminary Report on Patentability issued Dec. 26, 2017 for International Application No. PCT/US2016/038702, entitled “Combination Therapies for Heme Malignancies With Anti-CD38 Antibodies and Survivin Inhibitors”.Applicant
• International Search Report and Written Opinion mailed Nov. 29, 2016 for International Application No. PCT/US2016/038702, entitled “Combination Therapies for Heme Malignancies With ANTI-CD38 Antibodies and Survivin Inhibitors”.Applicant
• International Preliminary Report on Patentability issued Mar. 14, 2017 for International Application No. PCT/US2015/048899, entitled “Combination Therapies With Anti-CD38 Antibodies”.Applicant
• International Search Report and Written Opinion mailed Apr. 8, 2016 for International Application No. PCT/US2015/048899, entitled “Combination Therapies With Anti-CD38 Antibodies”.Applicant
• International Preliminary Report on Patentability issued Nov. 21, 2017 for International Application No. PCT/US2016/033544, entitled “Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies”.Applicant
• International Search Report and Written Opinion mailed Oct. 24, 2016 for International Application No. PCT/US2016/033544, entitled “Anti-CD38 Antibodies for Treatment of Light Chain Amyloidosis and Other CD38-Positive Hematological Malignancies”.Applicant
• International Preliminary Report on Patentability issued Jun. 6, 2016 for International Application No. PCT/US2015/063371, entitled “Anti-CD38 Antibodies for Treatment of Acute Myeloid Leukemia”.Applicant
• International Search Report and Written Opinion mailed Feb. 19, 2016 for International Application No. PCT/US2015/063371, entitled “Anti-CD38 Antibodies for Treatment of Acute Myeloid Leukemia”.Applicant
• International Preliminary Report on Patentability issued Dec. 26, 2017 for International Application No. PCT/US2016/039165, entitled “Immune Modulation and Treatment of Solid Tumors With Antibodies That Specifically Bind CD38”.Applicant
• International Search Report and Written Opinion mailed Oct. 14, 2016 for International Application No. PCT/US2016/039165, entitled “Immune Modulation and Treatment of Solid Tumors With Antibodies That Specifically Bind CD38”.Applicant
• International Preliminary Report on Patentability issued Sep. 6, 2016 for International Application No. PCT/US2015/017425, entitled “Anti-CD38 Antibodies for Treatment of Acute Lymphoblastic Leukemia”.Applicant
• International Search Report and Written Opinion mailed Sep. 21, 2015 for International Application No. PCT/US2015/017425, entitled “Anti-CD38 Antibodies for Treatment of Acute Lymphoblastic Leukemia”.Applicant
• International Preliminary Report on Patentability issued Jan. 10, 2019 for International Application No. PCT/EP2017/066063, entitled “Treatment of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38”.Applicant
• International Search Report and Written Opinion mailed Sep. 25, 2017 for International Application No. PCT/EP2017/066063, entitled “Treatment of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38”.Applicant
• International Preliminary Report on Patentability mailed May 14, 2020 for International Application No. PCT/US2018/058561, entitled “Methods of Treating High Risk Multiple Myeloma”.Applicant
• International Search Report and Written Opinion mailed Feb. 12, 2019 for International Application No. PCT/US2018/058561, entitled “Methods of Treating High Risk Multiple Myeloma”.Applicant
• International Preliminary Report on Patentability mailed Apr. 29, 2021 for International Application No. PCT/US2019/056838, entitled “Method of Providing Subcutaneous Administration of Anti-CD38 Antibodies”.Applicant
• International Search Report and Written Opinion mailed Apr. 24, 2020 for International Application No. PCT/US2019/056838, entitled “Method of Providing Subcutaneous Administration of Anti-CD38 Antibodies”.Applicant
• International Preliminary Report on Patentability issued Sep. 6, 2016 for International Application No. PCT/US2015/017420, entitled “Combination Therapies With Anti-CD38 Antibodies”.Applicant
• International Search Report and Written Opinion mailed Jul. 8, 2015 for International Application No. PCT/US2015/017420, entitled “Combination Therapies With Anti-CD38 Antibodies”.Applicant
• International Preliminary Report on Patentability for International Application No. PCT/IB2020/051484, mailed Sep. 2, 2021.Applicant
• International Search Report and Written Opinion for International Application No. PCT/IB2020/051484, mailed Jul. 2, 2020.Applicant
• Intellectual Property Office of Singapore Written Opinion dated Apr. 17, 2018 for Application No. 11201701867S, entitled “Combination Therapies with Anti-CD38 Antibodies”.Applicant
• Decision Revoking the European Patent issued in EP Patent No. 3370770, mailed Apr. 20, 2023; 22 Pages.Applicant
• Declaration of Professor Paul Anthony Dalby, in Opposition Proceedings against European Patent No. 3370770, 20 pages (Dated May 2022).Applicant
• Declaration of Professor Christian Jackisch, in Opposition Proceedings against European Patent No. 3370770, 8 pages (Dated May 10, 2022).Applicant
• Declaration of Professor Adrian Llewellyn Harris, in Opposition Proceedings against European Patent No. 3370770, 109 pages (Dated Dec. 20, 2022).Applicant
• Declaration of Dr. Richard Senderoff, in Opposition Proceedings against European Patent No. 3370770, 28 pages (Dated Dec. 20, 2022).Applicant
• Declaration of Professor Dr. Andreas Zimmer, in Opposition Proceedings against European Patent No. 3370770, 5 pages (Dated Jan. 9, 2023).Applicant
• Declaration of Professor Paul Anthony Dalby, in Opposition Proceedings against European Patent No. 3827845, 20 pages (Dated Jul. 19, 2023).Applicant
• Declaration of Peter Hellemans, in Opposition Proceedings against European Patent No. 3827845, 5 pages (Dated Jul. 21, 2023).Applicant
• Declaration of Tara Masterson, in Opposition Proceedings against European Patent No. 3827845, 4 pages (Dated Jul. 2023).Applicant
• Declaration of Professor Christian Jackisch, in Opposition Proceedings against European Patent No. 3827845, 11 pages (Dated Jul. 19, 2023).Applicant
• Second Declaration of Professor Christian Jackisch, in Opposition Proceedings against European Patent No. 3370770, 8 pages (Dated Jan. 6, 2023).Applicant
• Notice of Opposition Dated Oct. 20, 2021 by Opponent König Szynka Tilmann von Renesse, filed in European Patent No. 3 370 770 B1.Applicant
• Notice of Opposition Dated Oct. 19, 2021 by Opponent Patent Boutique LLP, filed in European Patent No. 3 370 770 B1.Applicant
• Notice of Opposition Dated Oct. 20, 2021 by Opponent Dr. Markus Breuer, filed in European Patent No. 3 370 770 B1.Applicant
• Notice of Opposition Dated Dec. 22, 2022 by Opponent Dr. Hans Ulrich Dorries, filed in European Patent No. 3 827 845 B1; 44 Pages.Applicant
• Notice of Opposition Dated Dec. 27, 2022 by Opponent Konig Szynka Tilmann von Renesse, filed in European Patent No. 3 827 845 B1; 49 Pages.Applicant
• Notice of Opposition Dated Dec. 28, 2022 by Opponent Michalski Huttermann & Partner, filed in European Patent No. 3 827 845 B1; 44 Pages.Applicant
• Notice of Opposition Dated Dec. 29, 2022 by Opponent Patent Boutique LLP, filed in European Patent No. 3 827 845 B1; 49 Pages.Applicant
• Notice of Opposition Dated Dec. 21, 2022 by Opponent Xbrane Biopharma AB, filed in European Patent No. 3 827 845 B1; 68 Pages.Applicant
• Opponent's submission by Dr. Markus Breuer dated Oct. 4, 2022 filed in European Patent No. 3 370 770 B1.Applicant
• Opponent's submission by Konig Szynka Tilmann von Renesse dated Jan. 11, 2023, filed in European Patent No. 3 370 770 B1; 27 Pages.Applicant
• Opponent's submission by Dr. Markus Breuer dated Jan. 13, 2023, filed in European Patent No. 3 370 770 B1; 11 Pages.Applicant
• Opponent's submission by Patent Boutique LLP dated Jan. 12, 2023, filed in European Patent No. 3 370 770 B1; 56 Pages.Applicant
• Provision of a the Minutes in Accordance with Rule 124(4) EPC regarding EP Patent No. 3370770, mailed Apr. 20, 2023, 14 pages.Applicant
• Reply to Notice of Opposition, filed in European Patent No. 3 370 770 B1, entitled: “Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses,” 416 pages, dated May 12, 2022.Applicant
• Reply to Notice of Opposition, filed in European Patent No. 3 370 770 B1, entitled: “Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses,” 19 pages, dated Jan. 13, 2023.Applicant
• Reply of the Patentee to the Notices of Opposition in European Patent No. 3 827 845 B1, Jul. 23, 2023 (203 pages).Applicant
• Supplementary European Search Report dated Feb. 21, 2018 for European Application No. EP 15839752 , entitled “Combination Therapies with Anti-CD38 Antibodies”.Applicant
• English translation of Office Action for JP Application No. 2016-554350, mailed Nov. 27, 2018.Applicant
• Non Final Office Action for U.S. Appl. No. 15/340,290 date mailed Nov. 20, 2017.Applicant
• Final Office Action for U.S. Appl. No. 15/340,290 date mailed May 16, 2018.Applicant
• Non Final Office Action for U.S. Appl. No. 15/340,290 date mailed Oct. 10, 2018.Applicant
• Final Office Action for U.S. Appl. No. 15/340,290 date mailed Mar. 11, 2019.Applicant
• Notice of Allowance for U.S. Appl. No. 15/340,290 date mailed May 22, 2019.Applicant
• Non Final Office Action for U.S. Appl. No. 15/366,474 date mailed Nov. 20, 2017.Applicant
• Final Office Action for U.S. Appl. No. 15/366,474 date mailed May 16, 2018.Applicant
• Applicant Initiated Interview for U.S. Appl. No. 15/366,474 date mailed Sep. 17, 2018.Applicant
• Non Final Office Action for U.S. Appl. No. 15/366,474 date mailed Oct. 11, 2018.Applicant
• Notice of Allowance for U.S. Appl. No. 16/380,994 date mailed Aug. 12, 2020.Applicant
• Notice of Allowance for U.S. Appl. No. 16/380,994 date mailed May 12, 2020.Applicant
• Notice of Allowance for U.S. Appl. No. 16/460,754 date mailed Sep. 10, 2020.Applicant
• Notice of Allowance for U.S. Appl. No. 16/460,754 date mailed May 18, 2020.Applicant
• Non Final Office Action for U.S. Appl. No. 16/840,153 date mailed Aug. 16, 2022.Applicant
• Applicant Initiated Interview Summary for U.S. Appl. No. 16/840,153 date mailed Jun. 8, 2022.Applicant
• Non Final Office Action for U.S. Appl. No. 16/840,153 date mailed Mar. 22, 2022.Applicant
• Applicant Initiated Interview Summary for U.S. Appl. No. 16/840,153 date mailed Apr. 6, 2022.Applicant
• Notice of Allowance for U.S. Appl. No. 16/840,153 date mailed Dec. 21, 2022.Applicant
• Non Final Office Action for U.S. Appl. No. 16/927,947 date mailed Mar. 7, 2023.Applicant
• Applicant Initiated Interview Summary for U.S. Appl. No. 16/927,947 date mailed Apr. 19, 2023.Applicant
• Notice of Allowance for U.S. Appl. No. 16/927,947 date mailed Jun. 22, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 17/116,822 date mailed Mar. 8, 2023.Applicant
• Applicant Initiated Interview Summary for U.S. Appl. No. 17/116,822 date mailed Apr. 19, 2023.Applicant
• Notice of Allowance for U.S. Appl. No. 17/116,822 date mailed May 12, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 17/116,835 date mailed Mar. 8, 2023.Applicant
• Applicant Initiated Interview Summary for U.S. Appl. No. 17/116,835 date mailed Apr. 19, 2023.Applicant
• Notice of Allowance for U.S. Appl. No. 17/116,835 date mailed May 11, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 15/189,577 date mailed Oct. 31, 2017.Applicant
• Final Office Action for U.S. Appl. No. 15/189,577 date mailed Apr. 13, 2018.Applicant
• Non Final Office Action for U.S. Appl. No. 15/189,577 date mailed Sep. 28, 2018.Applicant
• Notice of Allowance for U.S. Appl. No. 15/189,577 date mailed Mar. 31, 2020.Applicant
• Notice of Allowance for U.S. Appl. No. 15/189,577 date mailed Mar. 5, 2019.Applicant
• Notice of Allowance for U.S. Appl. No. 15/189,577 date mailed Sep. 12, 2019.Applicant
• Notice of Allowance for U.S. Appl. No. 15/189,577 date mailed Dec. 19, 2019.Applicant
• Non Final Office Action for U.S. Appl. No. 14/847,428 date mailed Sep. 23, 2016.Applicant
• Non Final Office Action for U.S. Appl. No. 15/386,391 date mailed Jun. 18, 2018.Applicant
• Final Office Action for U.S. Appl. No. 15/386,391 date mailed Dec. 28, 2018.Applicant
• Notice of Allowance for U.S. Appl. No. 15/386,391 date mailed Mar. 29, 2019.Applicant
• Notice of Allowance for U.S. Appl. No. 15/386,391 date mailed Jul. 30, 2019.Applicant
• Notice of Allowance for U.S. Appl. No. 15/386,391 date mailed Nov. 18, 2019.Applicant
• Non Final Office Action for U.S. Appl. No. 15/160,476 date mailed Sep. 15, 2017.Applicant
• Non Final Office Action for U.S. Appl. No. 15/160,476 date mailed Nov. 5, 2018.Applicant
• Final Office Action for U.S. Appl. No. 15/160,476 date mailed Apr. 23, 2018.Applicant
• Notice of Allowance for U.S. Appl. No. 15/160,476 date mailed May 4, 2020.Applicant
• Final Office Action for U.S. Appl. No. 15/160,476 date mailed Jun. 14, 2019.Applicant
• Non Final Office Action for U.S. Appl. No. 15/160,476 date mailed Dec. 20, 2019.Applicant
• Non Final Office Action for U.S. Appl. No. 16/986,214 date mailed Feb. 28, 2023.Applicant
• Final Office Action for U.S. Appl. No. 16/986,214 date mailed Aug. 23, 2023.Applicant
• Applicant Initiated Interview for U.S. Appl. No. 16/986,214 date mailed Oct. 17, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 14/956,890 date mailed Nov. 25, 2016.Applicant
• Final Office Action for U.S. Appl. No. 14/956,890 date mailed Jul. 24, 2018.Applicant
• Final Office Action for U.S. Appl. No. 14/956,890 date mailed Jan. 14, 2019.Applicant
• Non-Final Office Action for U.S. Appl. No. 14/956,890 date mailed Jul. 30, 2019.Applicant
• Final Office Action for U.S. Appl. No. 14/956,890 date mailed Jan. 7, 2020.Applicant
• Notice of Allowance for U.S. Appl. No. 14/956,890 date mailed Jul. 29, 2020.Applicant
• Non-Final Office Action for U.S. Appl. No. 17/005,039 date mailed Dec. 9, 2022.Applicant
• Final Office Action for U.S. Appl. No. 17/005,039 date mailed Apr. 28, 2023.Applicant
• Non-Final Office Action for U.S. Appl. No. 17/005,039 date mailed Sep. 1, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 15/340,214 date mailed May 16, 2018.Applicant
• Notice of Allowance for U.S. Appl. No. 16/162,355 mailed Apr. 9, 2021.Applicant
• Non-Final Office Action for U.S. Appl. No. 16/162,355 mailed Aug. 13, 2020.Applicant
• Non Final Office Action for U.S. Appl. No. 14/629,965 date mailed Dec. 21, 2015.Applicant
• Final Office Action for U.S. Appl. No. 14/629,965 date mailed Apr. 29, 2016.Applicant
• Notice of Allowance for U.S. Appl. No. 14/629,965 date mailed Apr. 13, 2017.Applicant
• Non Final Office Action for U.S. Appl. No. 15/651,333 date mailed Sep. 27, 2018.Applicant
• Notice of Allowance for U.S. Appl. No. 15/651,333 date mailed May 31, 2019.Applicant
• Notice of Allowance for U.S. Appl. No. 15/651,333 date mailed Oct. 9, 2019.Applicant
• Notice of Allowance for U.S. Appl. No. 15/651,333 date mailed Feb. 21, 2019.Applicant
• Non Final Office Action for U.S. Appl. No. 16/741,542 date mailed Jul. 12, 2022.Applicant
• Notice of Allowance for U.S. Appl. No. 16/741,542 date mailed Nov. 2, 2022.Applicant
• Non Final Office Action for U.S. Appl. No. 16/741,542 date mailed Mar. 17, 2023.Applicant
• Notice of Allowance for U.S. Appl. No. 16/741,542 date mailed Apr. 10, 2023.Applicant
• Non-Final Office Action for U.S. Appl. No. 16/312,133 mailed Oct. 28, 2021.Applicant
• Notice of Allowance for U.S. Appl. No. 16/312,133 mailed Sep. 2, 2022.Applicant
• Final Office Action for U.S. Appl. No. 16/312,133 mailed May 12, 2022.Applicant
• Non-Final Office Action for U.S. Appl. No. 16/312,133 mailed Dec. 8, 2022.Applicant
• Non-Final Office Action for U.S. Appl. No. 15/798,670 mailed Jan. 22, 2020.Applicant
• Final Office Action for U.S. Appl. No. 15/798,670 mailed Aug. 10, 2021.Applicant
• Non-Final Office Action for U.S. Appl. No. 15/798,670 mailed Apr. 2, 2021.Applicant
• Final Office Action for U.S. Appl. No. 15/798,670 mailed Dec. 16, 2020.Applicant
• Non-Final Office Action for U.S. Appl. No. 15/798,670 mailed Aug. 7, 2020.Applicant
• Non-Final Office Action for U.S. Appl. No. 15/798,670 mailed Feb. 4, 2022.Applicant
• Non-Final Office Action for U.S. Appl. No. 16/177,239 mailed Sep. 21, 2021.Applicant
• Final Office Action for U.S. Appl. No. 16/177,239 mailed Feb. 10, 2021.Applicant
• Non-Final Office Action for U.S. Appl. No. 16/177,239 mailed Aug. 24, 2020.Applicant
• Notice of Allowance for U.S. Appl. No. 16/177,239, mailed Oct. 13, 2022.Applicant
• Final Office Action for U.S. Appl. No. 16/177,239 date mailed Mar. 4, 2022.Applicant
• Notice of Allowance for U.S. Appl. No. 16/177,239 date mailed Feb. 3, 2023.Applicant
• Notice of Allowability for U.S. Appl. No. 16/177,239, mailed Feb. 27, 2023.Applicant
• Non-Final Office Action for U.S. Appl. No. 16/656,569 mailed Aug. 26, 2021.Applicant
• Notice of Allowance for U.S. Appl. No. 15/445,225 date mailed Mar. 25, 2020.Applicant
• Notice of Allowance for U.S. Appl. No. 15/445,225 date mailed Jul. 15, 2020.Applicant
• Notice of Allowance for U.S. Appl. No. 15/445,225 date mailed Dec. 4, 2019.Applicant
• Notice of Allowance for U.S. Appl. No. 15/445,225 date mailed Jul. 29, 2019.Applicant
• Non Final Office Action for U.S. Appl. No. 15/445,225 date mailed Jun. 29, 2018.Applicant
• Final Office Action for U.S. Appl. No. 15/445,225 date mailed Dec. 17, 2018.Applicant
• Non Final Office Action for U.S. Appl. No. 17/015,017 date mailed Dec. 23, 2022.Applicant
• Final Office Action for U.S. Appl. No. 17/015,017 date mailed Apr. 3, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 17/015,017 date mailed Aug. 18, 2023.Applicant
• Notice of Allowance for U.S. Appl. No. 17/015,017 date mailed Nov. 29, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 17/002,860 date mailed Jun. 27, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 17/691,050 date mailed Oct. 3, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 17/674,397 date mailed Apr. 24, 2023.Applicant
• Final Office Action for U.S. Appl. No. 17/674,397 date mailed Oct. 18, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 16/797,301 date mailed Jul. 28, 2022.Applicant
• Final Office Action for U.S. Appl. No. 16/797,301 date mailed Feb. 17, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 16/797,301 date mailed Sep. 22, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 17/475,975 date mailed Mar. 10, 2023.Applicant
• Non Final Office Action for U.S. Appl. No. 16/830,585 date mailed Mar. 17, 2022.Applicant
• Final Office Action for U.S. Appl. No. 16/830,585 date mailed Oct. 26, 2022.Applicant
• Non Final Office Action for U.S. Appl. No. 16/830,763 date mailed Mar. 17, 2022.Applicant
• Final Office Action for U.S. Appl. No. 16/830,763 date mailed Oct. 24, 2022.Applicant
• Non Final Office Action for U.S. Appl. No. 16/830,810 date mailed Mar. 15, 2022.Applicant
• Final Office Action for U.S. Appl. No. 16/830,810 date mailed Oct. 25, 2022.Applicant
• Non Final Office Action for U.S. Appl. No. 16/830,909 date mailed Mar. 17, 2022.Applicant
• Final Office Action for U.S. Appl. No. 16/830,909 date mailed Oct. 26, 2022.Applicant
• Abraham et al., ‘Real-life’ effectiveness studies of omalizumab in adult patients with severe allergic asthma: systematic review, Allergy 71(5):593-610 (2016).Applicant
• Anderson et al., Multiple Myeloma, Version 1.2013 in: Journal of the National Comprehensive Cancer Network vol. 11 Issue 1 (2013).Applicant
• Askmyr, et al.; Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 2013; 121 (18): 3709-3713.Applicant
• Baena-Cagnani & Gómez, Current status of therapy with omalizumab in children, Curr Opin Allergy Clin Immunol. 14(2):149-54 (2014).Applicant
• Bashir, Q. and Acosta, M., “Comparative Safety, Bioavailability, and Pharmacokinetic of Oral Dexamethasone, 4-mg and 20-mg tablets, in Healthy Volunteers Under Fasting and Fed Conditions: A Randomized Open-Label, 3-way Crossover Study,” Clinical Lymphoma, Myeloma & Leukemia, vol. 20; No. 11; 768-773 (2020).Applicant
• Blade, J. et al., “Immunoglobulin D multiple myeloma: presenting features, response to therapy, and survival in a series of 53 cases,” J Clin Oncol., vol. 12; No. 11; 2398-404 (1994).Applicant
• Briney, B. et al., “Commonality despite exceptional diversity in the baseline human antibody repertoire,” Nature, vol. 566; No. 7744; 393-397 (2019).Applicant
• Caraccioio, D. et al., “Exploiting MYC-induced PARPness to target genomic instability in multiple myeloma,” Haematologica, vol. 106; No. 1; 185-195 (2021).Applicant
• CAS Registry Results, Registry No. 945721-28-8, “Daratumumab,” 3 pages (2024).Applicant
• Cavo, M. et al., “Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma,” Blood, vol. 120; No. 1; 9-19 (2012).Applicant
• Cavo et al. “Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.” Lancet (Year: 2010).Applicant
• Chari et al. Subcutaneous daratumumab (DARA) in patients (PTs) with relapsed or refractory multiple myeloma (RRMM): Part 2 update of the open-label, multicenter, dose escalation phase 1 b study (PAVO). Hematologic Malignancies-Plasma Cell Dyscrasia, Jun. 1, 2018, Abstact: 8013. (Year: 2018).Applicant
• Chen, L. et al., “CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1/PD-L1 Blockade,” Cancer Discovery, vol. 8; No. 9; 1156-1175 (2018).Applicant
• CHMP Assessment Report for HyQvia, 68 pages (2013).Applicant
• ClinicalTrials.gov, “Daratumumab, Thalidomide and Dexamethasone in Relapse and/or Refractory Myeloma,” Identifier: NCT03143036; Last Update: Jun. 7, 2018 (15 pages).Applicant
• ClinicalTrials.gov Identifier: NCT02519452 “A Study of Daratumumab With the Addition of Recombinant Human Hyaluronidase (rHuPH20) for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma” First received: Aug. 6, 2015; Last updated: Sep. 18, 2015.Applicant
• ClinicalTrials.gov Identifier: NCT00950300 “A Study to Compare Subcutaneous (SC) Versus Intravenous (IV) Administration of Trastuzumab (Herceptin) in Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Early Breast Cancer” First submitted: Jul. 30, 2009; Last updated: Jan. 23, 2018.Applicant
• Comenzo, R. et al., ‘Dose-intensive melphalan with blood stemcell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients’, Blood, vol. 91, No. 10, pp. 3662-3670 (1998).Applicant
• Dakhil, S. et al., “Phase III safety study of rituximab administered as a 90-minute infusion in patients with previously untreated diffuse large B-cell and follicular lymphoma,” Leukemia & Lymphoma, vol. 55; No. 10; 2335-2340 (2014).Applicant
• Dasgupta et al., The effects of rituximab on serum IgE and BAFF, Allergy Asthma Clin Immunol. 9(1):39 (2013).Applicant
• De la Lastra, P. et al., “Epitope mapping of 10 monoclonal antibodies against the pig analogue of human membrane cofactor protein (MCP),” Immunology, vol. 96; No. 4; 663-670 (1999).Applicant
• Dhodapkar, M.V. et al., “Treatment of AL-Amyloidosis with Dexamethasone Plus Alpha Interferon,” Leukemia & Lymphoma, vol. 27; No. 3-4; 351-356 (1997).Applicant
• Dispenzieri, A. et al., ‘Activity of pomalidomide in patients with immunoglobulin light-chain amyloidosis’, Blood, vol. 119, No. 23, pp. 5397-5404 (2012).Applicant
• Fasan, A. et al., “The role of different genetic subtypes of CEBPA mutated AML,” Leukemia, 28.4: 794-803 (2014).Applicant
• Felgar, R.E. et al., CD38: an ‘orphan’ protein that may be finding a home? Leukemia Research, 24.2; 161-162 (2000).Applicant
• Gauvreau et al., Targeting membrane-expressed IgE B cell receptor with an antibody to the M1 prime epitope reduces IgE production, Sci Transl Med. 6(243):243ra85 (2014).Applicant
• Genmab, “Genmab Announces Positive Topline Results in Phase III Cassiopeia Study of Daratumumab in Front Line Multiple Myeloma,” Genmab News, 4 Pages (2018).Applicant
• Green, C. L. et al., The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood, The Journal of the American Society of Hematology, 118.2: 409-412 (2011).Applicant
• Heath, E.M. et al., “Biological and clinical consequences of NPM1 mutations in AML,” Leukemia, 31.4: 798-807 (2017).Applicant
• Hemady et al., Effect of dexamethasone on de novo IgE synthesis by human blood lymphocytes, J Allergy Clin Immunol. 75(2):304-12 (1985).Applicant
• Henig, I. and Zuckerman, T., “Hematopoietic Stem Cell Transplantation—50 Years of Evolution and Future Perspectives,” Rambam Maimonides Med J., vol. 5; Issue 4; e0028; 15 pages (2014).Applicant
• Highlights of Prescribing Information, Darzalex, 27 pages (2015); Revised Nov. 2016.Applicant
• Holien, T. et al., “Addiction to c-MYC in multiple myeloma,” Blood, vol. 120; No. 12; 4 pages (2012).Applicant
• Ichii, M. et al., “The Utility of Flow Cytometry in Evaluating Prognostic Factors of Multiple Myeloma,” Cytometry Research, vol. 23; No. 2; 7 pages (2013).Applicant
• Ishida, T., “Cytogenetic abnormalities in high-risk multiple myeloma,” Nihon Rinsho, vol. 73, Issue 1, pp. 28-32 (2015).Applicant
• Janeway, C.A. et al., “Structure of the Antibody Molecule and Immunoglobulin Genes,” Immunobiology: The Immune System in Health and Disease, 1997 Garland Publishing Inc., 3:1-3:11 (1997).Applicant
• Karakasheva, T.A. et al., “Abstract 3175: CD38-expressing myeloid-derived suppressor cells promote tumor growth in a murine model of esophageal cancer,” Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; Apr. 18-22, 2015; Philadelphia, PA.Applicant
• Kastritis, E. et al., “Bortezomib With or Without Dexamethasone in Primary Systemic (Light Chain) Amyloidosis,” J. Clin. Oncol., vol. 28; 1031-1037 (2010).Applicant
• Kaufman et al. Corticosteroid Tapering in Patients with Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab: Part 3 of the Open-Label, Multicenter, Phase 1 b PAVO Study. (J HOP. Mar. 2021, vol. 11, Special Feature, Abstract #CT04. (Year: 2021).Applicant
• Kegg Drug: Daratumumab; Retrieved from Internet URL: https://www.genome.jp/dbget-bin/www_bget?dr:D10777; retrieved on Oct. 17, 2024; 2 pages.Applicant
• Keyhani, A. et al., “Increased CD38 expression is associated with favorable prognosis in adult acute leukemia,” Leukemia research, 24.2: 153-159 (2000).Applicant
• Kumar,S.K. et al., “Treating Multiple Myeloma Patients with Oral Therapies,” Clinical Lymphoma, Myeloma & Leukemia, vol. 17; No. 5; 243-251 (2017).Applicant
• Kumar, S.K. et al., ‘Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial’, Blood, vol. 119, No. 21, pp. 4860-4867 (2012).Applicant
• Ley, T.J. et al., “DNMT3A mutations in acute myeloid leukemia,” New England Journal of Medicine, 363.25: 2424-2433 (2010).Applicant
• Lokhorst, H.M., “Dose-Dependent efficacy of daratumumab (DARA) as monotherapy in patients with relapsed or refractory multiple myeloma (RR MM),” Journal of Clinical Oncology, vol. 32; No. 15; 4 pages (2014).Applicant
• Lonial, S. et al., “Phase II study of daratumumab (DARA) monotherapy in patients with greater than or equal to 3 lines of prior therapy or double refractory multiple myeloma (MM): 54767414MMY2002 (Sirius),” Identifier: NCT01985126; Presented at ASC Annual Meeting (2015).Applicant
• Macro, M. et al., “Ixazomib and Daratumumab without Dexamethasone (I-Dara) in Elderly Frail RRMM Patients. A Multicenter Phase 2 Study (IFM Feb. 2018) of the Intergroupe Francophone Du Myelome (IFM),” Blood, Volo. 138; Supplemental_1; 83; 2 pages (2021).Applicant
• Masiuk et al., Improving Gene Therapy Efficiency through the Enrichment of Human Hematopoietic Stem Cells, Mol Ther. 25(9):2163-75 (2017).Applicant
• Morcos, P.N. et al., “Pharmacokinetics and pharmacodynamics of single subcutaneous doses of tocilizumab administered with or without rHuPH20,” International Journal of Clinical Pharmacology and Therapeutics, vol. 15, No. Jul. 2013; 537-548 (2013).Applicant
• Moreau, P. et al., “An Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Backbone Regimens in Patients with Multiple Myeloma,” Blood, vol. 124; No. 21; 176 (2014).Applicant
• Moreau, P. et al., “Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (Cassiopeia): a randomised, open label, phase 3 study,” Lancet, vol. 394; 29-38 (2019).Applicant
• Nahi et al. Corticosteroid Tapering in Patients With Relapsed or Refractory Multiple Myeloma Receiving Subcutaneous Daratumumab (DARA SC): Part 3 of the Open-label, Multicenter, Phase 1 b PAVO Study. Abstract release date May 14, 2020) EHA library, Jun. 12, 2020, 293526, EP1038. (Year: 2020).Applicant
• Narayanan, S. et al., “Poly (ADP-ribose) polymerase (PARP) inhibitors as chemosensitizing compounds for the treatment of drug resistant cancers,” J. Mol. Clin. Med., vol. 2; No. 3; 55-67 (2019).Applicant
• Nau, K.C. et al., ‘Multiple Myeloma: Diagnosis and Treatment’, American Family Physician , vol. 78, No. 7, pp. 853-859 (2008).Applicant
• Neri, P. et al., “Bortezomib-induced “BRCAness” sensitizes multiple myeloma cells to PARP inhibitors,” Blood, vol. 118; No. 24; 6368-6379 (2011).Applicant
• Palumbo, A. et al., “Melphalan 200 mg/m2 versus melphalan 100 mg/m2 in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study,” Blood, vol. 115; No. 10; 1873-1879 (2010).Applicant
• Palumbo, A. et al., “Phase III randomized controlled study of daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in patients (pts) with relapsed or refractory multiple myeloma (RRMM): Castor study,” Journal of Clinical Oncology, vol. 34; Suppl. 18; 3 pages (2016).Applicant
• Peña O C, Intriago B M, Gray H AM, Cabrera C ME. Amiloidosis extrema asociada a mieloma múltiple e insuficiencia renal terminal: Caso clínico [Primary amyloidosis associated with multiple myeloma and renal failure: case report]. Rev Med Chil. Nov. 2011; 139(11):1471-4. Spanish. Epub Feb. 8, 2012. (English Abstract included).Applicant
• Quartino, A.L. et al., “Population pharmacokinetic and exposure-response analysis for trastuzumab administered using a subcutaneous “manual syringe” injection or intravenously in women with HER2-positive early breast cancer,” Cancer Chemother Pharmacol, vol. 77; 77-88 (2016).Applicant
• Rajkumar, S.V. et al., “Multiple Myeloma: 2018 update on Diagnosis, Risk-stratification and Management,” Am J. Hematol, vol. 93; No. 8; 981-1114 (2019).Applicant
• Rajkumar, S.V. et al., “Multiple Myeloma: Diagnosis and Treatment,” Mayo Clin Proc., vol. 91; No. 1; 101-119 (2016).Applicant
• Rituxan (tituximab), Highlights of prescribing information. Rituxan (IV administered Rituximab; 53 pages (1997); Revised 2021.Applicant
• Rivkin, S.E. et al., “Phase lb with expansion study of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients,” Int. J. Gynecol. Cancer, vol. 29; 325-333 (2019).Applicant
• Rosenberg et al., A role for plasma cell targeting agents in immune tolerance induction in autoimmune disease and antibody responses to therapeutic proteins, Clin Immunol. 165:55-9 (2016).Applicant
• San-Miguel, J. et al., “Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: part 2 of the open-label, multicenter, dose-escalation phase Ib study (PAVO),” Haematologica, vol. 106; No. 6; 1725-1732 (2021); Suppl Appendix.Applicant
• San-Miguel J, et al. “Depth of Response and MRD with Daratumumab Plus Lenalidomide and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in RRMM: Pollux”. 16th International Myeloma Workshop; Mar. 2017. OP-028, p. e17-18.Applicant
• Seckinger, A. et al., “CD38 as Immunotherapeutic Target in Light Chain Amyloidosis and Multiple Myeloma—Associated with Molecular Entities, Risk, Survival, and Mechanisms of Upfront Resistance,” Frontiers in Immunology, vol. 9; Article 1676; 15 pages (2018).Applicant
• Shibayama, H. et al., “Subcutaneous delivery of daratumumab in Japanese patients with relapsed/refractory multiple myeloma,” Internationl Journal of Hematology, vol. 113; 112-121 (2021).Applicant
• Siddiqui, B.A. et al., “Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor),” ImmunoTherapy of Cancer, vol. e006262; 12 pages (2023).Applicant
• Small, D. et al., “FLT3 mutations: biology and treatment,” ASH Education Program Book, 1: 178-184 (2006).Applicant
• Spencer A, et al. “Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: Castor”. 16th International Myeloma workshop; Mar. 2017. PS-151(d), p. e85.Applicant
• Spencer, A. et al., Depth of Response and MRD with Daratumumab Plus Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in RRMM: Castor. Clinical Lymphoma Myeloma and Leukemia. vol. 17(1), Supplement, 2017; pp. e85.Applicant
• Stege, C.A.M. et al., “Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Trial,” Blood, vol. 134; Supplemental_1; 695; 4 pages (2019).Applicant
• Wasserman, R.L. et al., “Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency,” J Allergy Clin Immunol, vol. 130; 951-957 (2012).Applicant
• Wechalekar, A.D. et al., ‘Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis’, Blood, vol. 109, No. 2, pp. 457-464 (2006).Applicant
• Wegmann et al., Long-term bortezomib treatment reduces allergen-specific IgE but fails to ameliorate chronic asthma in mice, Int Arch Allergy Immunol. 158(1):43-53 (2012).Applicant
• Wood et al., A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy, J Allergy Clin Immunol. 137(4):1103-1110 (2016).Applicant
• Wu et al., Glucocorticoids increase the synthesis of immunoglobulin E by interleukin 4-stimulated human lymphocytes, J Clin Invest. 87(3):870-7 (1991).Applicant
• Wynne, C. et al., “Comparison of Subcutaneous and Intravenous Administration of Trastuzumab: A Phase I/Ib Trial in Healthy Male Volunteers and Patients with HER2-Positive Breast Cancer,” The Journal of Clinical Pharmacology, vol. 53; No. 2; 192-201 (2012).Applicant
• Annex to Form 2300—Notice of Opposition, filed on behalf of Konig Szynka Tilmann von Renesse, filed in Opposition for EP Patent 3370770, 39 pages (2024).Applicant
• DataSheet for the Decision of Jan. 17, 2025 issued in Opposition Proceedings against EP Patent No. 3370770, mailed Jan. 22, 2025; 6 pages.Applicant
• Decision Revoking European Patent and Minutes of the Oral proceedings, and associated documents in Opposition against EP Patent No. 3827845, dated Nov. 29, 2024 (47 pages).Applicant
• Decision of the Board of Appeals dated Jan. 17, 2025 for Patent No. EP3370770.Applicant
• Declaration of Peter Hellemans, in Opposition Proceedings against European Patent No. 3370770, 5 pages (Dated Aug. 24, 2023).Applicant
• Declaration of Tara Masterson, in Opposition Proceedings against European Patent No. 3370770, 4 pages (Dated Aug. 2023).Applicant
• Second Declaration of Professor Adrian Llewellyn Harris, in Opposition Proceedings against European Patent No. 3370770, 5 pages (Dated Jan. 3, 2024).Applicant
• Non-patent Literature filed by a third party during the appeal procedure for Opposition in EP Patent No. 4085929, 21 Pages (Dated Jun. 5, 2025).Applicant
• Non-patent Literature filed by a third party during the appeal procedure for Opposition in EP Patent No. 4085929, 18 Pages (Dated Jun. 5, 2025).Applicant
• Non-patent Literature filed by a third party during the appeal procedure for Opposition in EP Patent No. 4085929, 3 Pages (Dated Jun. 5, 2025).Applicant
• Opponent's submission by Dr. Markus Breuer dated Jan. 15, 2024, filed in European Patent No. 3 370 770 B1; 53 Pages.Applicant
• Opponents Submission by Dr. Markus Breuer to Comments on Proprietor's Submission , filed in EP Opposition for EP Patent 3370770, 17 pages; dated Oct. 4, 2022.Applicant
• Opponent's submission by Xbrane Biopharma AB dated Jul. 15, 2024, filed in European Patent No. 3 827 845 B1; 7 Pages.Applicant
• Opponent's submission by Patent Boutique LLP dated Aug. 23, 2024, filed in European Patent No. 3 827 845 B1; 52 Pages.Applicant
• Opponent's submission by Huttermann, dated Aug. 22, 2024, filed in European Patent No. 3 827 845 B1; 32 Pages.Applicant
• Opponent's submission by Ulrich Dorries, dated Aug. 23, 2024, filed in European Patent No. 3 827 845 B1; 22 Pages.Applicant
• Opponent's submission by Renesse, dated Aug. 22, 2024, filed in European Patent No. 3 827 845 B1; 14 Pages.Applicant
• Opponent's submission by Renesse, dated Nov. 12, 2024, filed in European Patent No. 3 827 845 B1; 7 Pages.Applicant
• Opponent's submission by Ulrich Dorries, dated Jun. 5, 2025, filed in Opposition against EP Patent No. 4085929; 7 pages.Applicant
• Patentee's Rejoinder, filed in Opposition Proceedings against EP 3770770, mailed Mar. 27, 2024; 72 pages.Applicant
• Patentee's Grounds of Appeal filed Mar. 31, 2025 for Patent No. EP3827845.Applicant
• Response to Patentee's submission filed Nov. 12, 2024 for Patent No. EP3370770.Applicant
• Patentee's Rejoinder in Response to Opponents' Reply to the Appeal filed Mar. 26, 2024 for Patent No. EP3370770.Applicant
• Representation for Indian Pharmaceutical Alliance in Opposition of Patent for IN Application No. 201617029321, dated May 10, 2022 (29 pages).Applicant
• Representation for Indian Pharmaceutical Alliance in Opposition of Patent for IN Application No. 201617029109, dated Feb. 24, 2022 (30 pages).Applicant
• Reply of the Patentee, Janssen Biotech, Inc., to the Notices of Opposition in European Patent No. 3370770, Aug. 2023 (63 pages).Applicant
• Reply to Notice of Opposition, filed in European Patent No. 3827845 B1, entitled: “Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses,” 18 pages, dated Oct. 14, 2024.Applicant
• Reply to Notice of Opposition, filed in European Patent No. 3827845 B1, entitled: “Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses,” 110 pages, dated Mar. 31, 2025.Applicant
• Response to Patentee's Statement of Grounds of Appeal, filed by Patent Boutique LLP in European Patent No. 3370770 , dated Jan. 12, 2024 (74 pages).Applicant
• Response to Patentee's Statement of Grounds of Appeal, filed on behalf of Konig Szynka Tilmann von Renesse in European Patent No. 3370770 , dated Jan. 15, 2024 (106 pages).Applicant
• Response to Summons to Attend Oral Proceedings in Opposition against EP 3770770, filed on behalf of Dr. Markus Breuer, 11 pages; filed on Jan. 13, 2023.Applicant
• Statement on a Nonproprietary Name Adopted by the United States Adopted Names (USAN) Council, Hyaluronidase (Human Recombinant) CAS Registry Number 757971-58-7 (no date provided).Applicant
• Summons to Attend Oral Proceedings dated Aug. 8, 2022 for Patent No. EP3370770.Applicant
• Information about results of Oral Proceedings during Opposition of EP 3827845 B1, titled “Subcutaneous Formulations of Anti-CD38 Antibodies and Their Uses,” dated Oct. 28, 2024, 2 pages.Applicant
• Non Final Office Action for U.S. Appl. No. 19/198,946 date mailed Jun. 20, 2025.Applicant
• Final Office Action for U.S. Appl. No. 19/198,946 date mailed Oct. 8, 2025.Applicant
• Notice of Allowance for U.S. Appl. No. 19/198,946 date mailed Jan. 6, 2026.Applicant
• Non Final Office Action for U.S. Appl. No. 16/986,214 date mailed Dec. 26, 2023.Applicant
• Notice of Allowance for U.S. Appl. No. 16/986,214 date mailed Jun. 7, 2024.Applicant
• Final Office Action for U.S. Appl. No. 17/005,039 date mailed Dec. 22, 2023.Applicant
• Non-Final Office Action for U.S. Appl. No. 17/005,039 date mailed Jul. 5, 2024.Applicant
• Notice of Allowance for U.S. Appl. No. 17/005,039 date mailed Jan. 8, 2025.Applicant
• Non-Final Office Action for U.S. Appl. No. 17/329,057 mailed Dec. 12, 2023.Applicant
• Final Office Action for U.S. Appl. No. 17/329,057 mailed Apr. 5, 2024.Applicant
• Non-Final Office Action for U.S. Appl. No. 18/329,443 mailed Jun. 18, 2024.Applicant
• Final Office Action for U.S. Appl. No. 18/329,443 mailed Feb. 6, 2025.Applicant
• Notice of Allowance for U.S. Appl. No. 18/329,443 mailed Sep. 16, 2025.Applicant
• Non Final Office Action for U.S. Appl. No. 18/175,345 date mailed Mar. 21, 2025.Applicant
• Final Office Action for U.S. Appl. No. 18/175,345 date mailed Oct. 16, 2025.Applicant
• Notice of Allowance for U.S. Appl. No. 17/015,017 date mailed Apr. 11, 2024.Applicant
• Final Office Action for U.S. Appl. No. 17/002,860 date mailed Nov. 30, 2023.Applicant
• Final Office Action for U.S. Appl. No. 17/002,860 date mailed Aug. 5, 2024.Applicant
• Final Office Action for U.S. Appl. No. 17/691,050 date mailed Mar. 8, 2024.Applicant
• Non Final Office Action for U.S. Appl. No. 17/691,050 date mailed Aug. 14, 2024.Applicant
• Final Office Action for U.S. Appl. No. 17/691,050 date mailed Feb. 28, 2025.Applicant
• Final Office Action for U.S. Appl. No. 17/691,050 date mailed Aug. 8, 2025.Applicant
• Non Final Office Action for U.S. Appl. No. 17/005,825 date mailed Feb. 28, 2024.Applicant
• Non Final Office Action for U.S. Appl. No. 17/005,825 date mailed Nov. 5, 2024.Applicant
• Final Office Action for U.S. Appl. No. 17/005,825 date mailed Aug. 26, 2025.Applicant
• Non Final Office Action for U.S. Appl. No. 17/674,397 date mailed Mar. 1, 2024.Applicant
• Final Office Action for U.S. Appl. No. 17/674,397 date mailed Oct. 9, 2024.Applicant
• Non-Final Office Action for U.S. Appl. No. 17/674,397 date mailed May 19, 2025.Applicant
• Final Office Action for U.S. Appl. No. 17/674,397 date mailed Dec. 3, 2025.Applicant
• Non Final Office Action for U.S. Appl. No. 17/980,149 date mailed Nov. 5, 2024.Applicant
• Non Final Office Action for U.S. Appl. No. 17/980,149 date mailed May 8, 2025.Applicant
• Non Final Office Action for U.S. Appl. No. 17/980,149 date mailed Nov. 28, 2025.Applicant
• Final Office Action for U.S. Appl. No. 16/797,301 date mailed Jan. 29, 2024.Applicant
• Non Final Office Action for U.S. Appl. No. 16/797,301 date mailed Sep. 25, 2024.Applicant
• Final Office Action for U.S. Appl. No. 16/797,301 date mailed Jan. 23, 2025.Applicant
• Non Final Office Action for U.S. Appl. No. 16/797,301 date mailed Aug. 18, 2025.Applicant
• Mateos, M. et al., “Efficacy of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Myeloma Based on Prior Lines of Therapy: Updated Analysis of Castor,” Blood, vol. 128; No. 22; 1150; 4 pages (2016).Applicant
• Yang, R. et al., “Conversion of ATP to adenosince by CD39 and CD73 in multiple myeloma can be successfully targeted together with adenosine receptor A2A blockade,” J. Immunother. Cancer; vol. 8; 14 pages (2020).Applicant
• Non Final Office Action for U.S. Appl. No. 19/311,965 date mailed Feb. 11, 2026.Applicant
• Non-Final Office Action for U.S. Appl. No. 19/449,026 date mailed Mar. 19, 2026.Applicant
• Non Final Office Action for U.S. Appl. No. 18/175,345 date mailed Feb. 18, 2026.Applicant
• Non Final Office Action for U.S. Appl. No. 19/418,902 date mailed Feb. 17, 2026.Applicant
• Final Office Action for U.S. Appl. No. 17/691,050 date mailed Oct. 3, 2023.Applicant
• Final Office Action for U.S. Appl. No. 16/797,301 date mailed Feb. 24, 2026.Applicant
• Kikukawa, Y., et al,: “Combined use of bortezomib, cyclophosphamide and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study”, International Journal of Hematology, vol. 101, Nov. 28, 2014, pp. 133-139.Applicant
• Non Final Office Action for U.S. Appl. No. 19/418,900 date mailed Mar. 30, 2026.Applicant
• Hamed, R.A. et al., “Current status of autologous stem cell transplantation for multiple myeloma,” Blood Cancer Journal, vol. 9; No. 44; 10 Pages (2019).Applicant
• Notice of Allowance for U.S. Appl. No. 19/311,965 date mailed Apr. 21, 2026.Applicant
• Final Office Action for U.S. Appl. No. 17/005,825 date mailed Apr. 20, 2026.Applicant
• American Society of Hematology (ASH) annual meeting Dec. 6-9, 2014 in San Francisco—Abstract 3450: Merlini, Giampaolo, et al. “Long-term outcome of a phase 1 study of the investigational oral proteasome inhibitor (PI) ixazomib at the recommended phase 3 dose (RP3D) in patients (Pts) with relapsed or refractory systemic light-chain (AL) amyloidosis (RRAL).” Blood 124.21 (2014): 3450.Applicant
• Avet-Loiseau, H. et al., “Evaluation of Sustained Minimal Residual Disease Negativity with Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and Castor,” J Clin Oncol., vol. 39; 1139-1149 (2021).Applicant
• Banerjee et al. “Past, Present, and Future of Dexamethasone in Multiple Myeloma and AL Amyloidosis” J Clin Oncol 44, 903-913(2026). DOI:10.1200/JCO-25-01713.Applicant
• Bertamini, et al. “Checkpoint inhibitors and myeloma: promises, deadlocks and new directions” Ann Transl Med. Jun. 2020;8(12):777. doi: 10.21037/atm.2020.02.65. PMID: 32647702; PMCID: PMC7333157.Applicant
• ClinicalTrials.gov identifier: NCT02312206 “The VITAL Amyloidosis Study, a Global Phase 3, Efficacy and Safety Study of NEOD001 in Patients With AL Amyloidosis (VITAL)”, Available: https://clinicaltrials.gov/study/NCT02312206?tab=history&a-6#version-content-panel; Last Update Nov. 14, 2023.Applicant
• Czuczman, M.S. et al., “Ofatumumab (OFA) in Combination with CHOP for Previously Untreated Follicular Lymphoma: Follow-up Results,” Blood, vol. 120; No. 21; 1632; 9 pages (2012).Applicant
• Desai, M. et al., Insights from a Survey of Drug Formulation Experts: Challenges and Preferences in High- Concentration Subcutaneous Biologic Drug Development 27(142) AAPS J. 1, 6 (2025).Applicant
• Desai, M. et al., Expert insights into the development of large-vol. subcutaneous drugs with permeation enhancers: A survey examining challenges, alternatives, and future directions, 689 Int'l J. Pharmaceutics 126515, at abstract (2026).Applicant
• “dezamizumab | Ligand page,” IUPHAR/BPS Guide to Pharmacology. Available: https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligan did=8255. (saved from website on Mar. 23, 2026).Applicant
• Dias, C. et al., Tolerability of High-vol. Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects, 16(5) Aaps Pharmscitech 1101, 1101 (2015) (“Dias 2015”).Applicant
• Donnelly, Joseph P., and Mazen Hanna. “Cardiac amyloidosis: an update on diagnosis and treatment.” Cleve Clin J Med 84.12 Suppl 3 (2017): 12-26.Applicant
• Drent, E. et al., “CD38 Chimeric Antigen Receptor Engineered T Cells As Therapeutic Tools for Multiple Myeloma,” Blood, vol. 124; No. 21; 4759; 8 pages (2014).Applicant
• Flynn, M.J. et al., “Pre-Clinical Activity of Adct-301, a Novel Pyrrolobenzodiazepine (PBD) Dimer-Containing Antibody Drug Conjugate (ADC) Targeting CD25-Expressing Hematological Malignancies,” Blood, vol. 124; No. 21; 4491; 9 pages (2014).Applicant
• Gibney, M., Halozyme Provides Update on ViroPharma Phase 2 Trial of Subcutaneous Cinryze (C1 Esterase Inhibitor [Human]) Formulation with rHuPH20, FIERCEPHARMA (Aug. 5, 2013), http://fiercepharma.com/drug-delivery/halozyme-provides-update-on-viropharma-phase-2-trial-of-subcutaneous-cinryze-cl (“Gibney 2013”).Applicant
• Global Genes. Alexion licenses Halozyme drug delivery technology in deal worth up to $680 million (Dec. 7, 2017), available https://globalgenes.org/blog/alexion-licenses- halozyme-drug-delivery-technology-in-deal-worth-up-to- 680-million.Applicant
• Herbert Irving Comprehensive Cancer Center (HICCC)—New York “Amyloidosis Symptoms & Diagnosis” https://www.cancer.columbia.edu/cancer-types-care/types/amyloidosis/about-amyloidosis (saved from website on Feb. 25, 2026).Applicant
• Highlights of Prescribing Information, Hylenex, FDA Label, 9 pages (2005); Revised Jan. 2024.Applicant
• Highlights of Prescribing Information, ULTOMIRIS® (ravulizumab-cwvz) injection, FDA Label, 56 pages (2018); Revised Mar. 2024.Applicant
• Kaiser et al. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. J Clin Oncol 41, 3945-3955(2023). DOI:10.1200/JCO.22.02567.Applicant
• Kinnunen, H.M. et al., Improving the outcomes of biopharmaceutical delivery via the subcutaneous route by understanding the chemical, physical and physiological properties of the subcutaneous injection site, 182 J. Controlled Release 22, 23 (2014) (“Kinnunen 2014”).Applicant
• Kumagai, Masa-aki, et al. “Ligation of CD38 suppresses human B lymphopoiesis.” The Journal of Experimental Medicine 181.3 (1995): 1101-1110.Applicant
• Larocca et al. Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myeloma. Blood. Jun. 3, 2021;137(22):3027-3036. doi: 10.1182/blood.2020009507. Erratum in: Blood. Feb. 1, 20236;141(7):809. doi: 10.1182/blood.2022018970. PMID: 33739404.Applicant
• Malavasi, Fabio, and Angelo Corso Faini. “Mechanism of action of a new anti-CD38 antibody: enhancing myeloma immunotherapy.” Clinical Cancer Research 25.10 (2019): 2946-2948.Applicant
• Manier et al. Safety and efficacy of a dexamethasone-sparing regimen with daratumumab and lenalidomide in patients with frailty and newly diagnosed multiple myeloma (IFM2017-03): a phase 3, open-label, multicentre, randomised, controlled trial. Lancet Oncol. Oct. 2025;26(10):1323-1333. doi: 10.1016/S1470-2045(25)00280-3. PMID: 41038184.Applicant
• Marco Jansen, J.H. et al. “Daratumumab, a Human CD38 Antibody Induces Apoptosis of Myeloma Tumor Cells Via Fc Receptor-Mediated Crosslinking,” Blood, vol. 120; No. 21; 2974; 7 pages (2012).Applicant
• Matas-Cespedes, A. et al., “Daratumumab, a Novel Human Anti-CD38 Monoclonal Antibody for the Treatment of Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma, ” Blood, vol. 120; No. 21; 3935; 8 pages (2012).Applicant
• Matas-Cespedes, A. et al., “Daratumumab, a Novel Anti-CD38 Monoclonal Antibody Shows Anti-Tumor Activty in CLL and hampers Leukemia-Microenvironment Interactions,” Blood, vol. 124; No. 21; 4680; 9 pages (2014).Applicant
• Merlini, Giampaolo, and Marvin J. Stone. “Dangerous small B-cell clones.” Blood 108.8 (2006): 2520-2530.Applicant
• Mitragotri, S. et al., “Overcoming the Challenges in Administering Biopharmaceuticals: Formulation and Delivery Strategies,” 13 Nature Rev. Drug Discov. 655, 656 (2014) (“Mitragotri 2014”).Applicant
• Moreno, et al. “The Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma” Clin Cancer Res May 15, 2019; 25 (10): 3176-3187. https://doi.org/10.1158/1078-0432.CCR-18-1597.Applicant
• Morra, Massimo, et al. “CD38 is functionally dependent on the TCR/CD3 complex in human T cells.” The FASEB journal 12.7 (1998): 581-592.Applicant
• Muchtar, Eli, et al. “From CyBorD to dara-CyBorD, ASCT utilization trends in AL amyloidosis: a 15-year analysis. ” Blood Advances 9.16 (2025): 4311-4316.Applicant
• Muchtar, Eli, et al. “Improved outcomes for newly diagnosed AL amyloidosis between 2000 and 2014: cracking the glass ceiling of early death.” Blood, The Journal of the American Society of Hematology 129.15 (2017): 2111-2119.Applicant
• Muchtar, Eli, and Morie A. Gertz. “Clinical trials evaluating potential therapies for light chain (AL) amyloidosis.” Expert Opinion on Orphan Drugs 5.8 (2017): 655-663.Applicant
• Mullin, R., Pfizer Discontinues Work on Bococizumab, CHEM. & Eng'g News (Nov. 5, 2016), available at https://cen.acs.org/articles/94/144/Pfizer-discontinues-work- bococizumab.html.Applicant
• Noort, W.A. et al., “Daratumumab, a Novel Human CD38 Monoclonal Antibody for Treatment of Multiple Myeloma, Prevents Intra-Medullary Spreading of Patient Derived Multiple Myeloma Cells Growing in a Humanized Mouse Model,” Blood, vol. 120; No. 21; 1834; 8 pages (2012).Applicant
• Noort, W.A. et al., “Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Refractory Patient-Derived Multiple Myeloma Cells, Growing in a Novel Humanized Mouse MM Model, ” Blood, vol. 120; No. 21; 1834; 8 pages (2012).Applicant
• Osterborg, A. et al., “Ofatumumab (OFA) Vs. Physician's Choice (PC) of Therapy in Patients (pts) with Bulky Fludarabine Refractory (BFR) Chronic Lymphocytic Leukaemia (CLL): Results of the Phase III Study OMB114242,” Blood, vol. 124; No. 21; 4684; 11 pages (2014).Applicant
• Overdijk, M.B. et al., “Phagocytosis Is A Mechanism of Action for Daratumumab,” Blood, vol. 120; No. 21; 4054; 8 pages (2012).Applicant
• Peipp, M. et al., “Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30,” Blood, vol. 124; No. 21; 1779; 8 pages (2014).Applicant
• Philippidis, A., Abb Vie Terminates Development Deal with Halozyme, Genetic Eng'g & Biotech. News (Nov. 21, 2016), available at https://www.genengnews.com/news/abbvie-terminates-development-deal-with-halozyme.Applicant
• Plesner, T. et al., “Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma—Data From a Dose-Escalation Phase I/II Study,” Blood, vol. 120; No. 21; 73; 9 pages (2012).Applicant
• Plesner, T. et al., “Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refrqactory Multiple Myeloma,” Blood, vol. 124; No. 21; 84; 9 pages (2014).Applicant
• “Prothena Initiates NEOD001 Global Phase 3 Registrational Trial Based on Positive Results in Ongoing Phase 1/2 Study of NEOD001 in Patients With AL Amyloidosis”, (published on 02.12.2014). Available: https://ir.prothena.com/investors/press-releases/news-details/2014/Prothena-Initiates-NEOD001-Global-Phase-3-Registrational- Trial-Based-on-Positive-Results-in-Ongoing-Phase-12-Study-of-NEOD001-in-Patients-With-AL-Amyloidosis/default.aspx.Applicant
• “Prothena's NEOD001 Demonstrates Encouraging Cardiac Biomarker Responses in Ongoing Phase 1 Study in Patients With Immunoglobulin Light Chain (AL) Amyloidosis”, (published on 23.04.2014). Available: https://ir.prothena.com/investors/press- releases/news-details/2014/Prothenas-NEOD001-Demonstrates-Encouraging-Cardiac- Biomarker-Responses-in-Ongoing-Phase-1-Study-in-Patients-With-Immunoglobulin- Light-Chain-AL-Amyloidosis/default.aspx.Applicant
• “Prothena Discontinues Development of NEOD001 for AL Amyloidosis”, (published on 23.04.2018). Available: https://ir.prothena.com/investors/press- releases/newsdetails/2018/Prothena-Discontinues-Development-of-NEOD001-for-AL-Amyloidosis/default.aspx.Applicant
• “Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint”, (published on 23.05.2025). Available: https://ir.prothena.com/investors/press-releases/news-details/2025/Prothena-Announces-Phase-3-AFFIRM-ALClinical-Trial-for-Birtamimab-in-Patients-with-AL-Amyloidosis-Did-Not-Meet-Primary-Endpoint/default.aspx.Applicant
• Raje, Noopur, and Dan L. Longo. “Monoclonal antibodies in multiple myeloma come of age.” New England Journal of Medicine 373.13 (2015): 1264-1266.Applicant
• Richards, Duncan B., et al. “Therapeutic clearance of amyloid by antibodies to serum amyloid P component.” New England Journal of Medicine 373.12 (2015): 1106-1114.Applicant
• Rivipansel Fails to Meet Phase III Trial Endpoints, Ash Clinical News (Dec. 30, 2021), https://ashpublications.org/ashclinicalnews/news/4709/Rivipansel-Fails-to-Meet- Phase-III-Trial-Endpoints.Applicant
• Salles, Gilles, et al. “Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma.” Clinical Lymphoma Myeloma and Leukemia 19.5 (2019): 275-284.Applicant
• Sanofi Press Release, ASCO: new Sarclisa data support subcutaneous administration with on-body injector, at 1 (Jun. 3, 2025).Applicant
• Sonneveld, P. et al., “Overall Survival with Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (Castor): A Randomized, Open-Label, Phase III Trial,” J Clin. Oncol., vol. 41; 1600-1609 (2022).Applicant
• Stevenson, Freda K., et al. “Preliminary studies for an immunotherapeutic approach to the treatment of human myeloma using chimeric anti-CD38 antibody.” (1991): 1071-1079.Applicant
• Tai, Yu-Tzu, and Kenneth C. Anderson. “Antibody-based therapies in multiple myeloma.” Bone marrow research 2011.1 (2011).Applicant
• Todisco, Elisabetta, et al. “CD38 ligation inhibits normal and leukemic myelopoiesis.” Blood, The Journal of the American Society of Hematology 95.2 (2000): 535-542.Applicant
• Van Imhoff, G,W. et al., “Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The Orcharrd Study (OMB110928),” Blood, vol. 124; No. 21; 630; 9 pages (2014).Applicant
• Van Oers, M.H.J. et al., “Ofatumumab (OFA) Maintenance Prolongs PFS in Relapsed CLL: Prolong Study Interim Analysis Results,” Blood, vol. 124; No. 21; 21; 10 pages (2014).Applicant
• Wang, W., Advanced Protein Formulations, 24 Protein Sci. 1031, abstract (2015) .Applicant
• Wang, Wei, et al. “NK cell-mediated antibody-dependent cellular cytotoxicity in cancer immunotherapy.” Frontiers in Immunology 6 (2015): 368.Applicant
• Xolair, Medication Guide, Prescribing Information, at 1 (Sep. 26, 2014); 3 pages.Applicant
• Zupo, Simona, et al. “CD38 signaling by agonistic monoclonal antibody prevents apoptosis of human germinal center B cells.” European Journal of Immunology 24.5 (1994): 1218-1222.Applicant
• Non Final Office Action for U.S. Appl. No. 19/449,144 date mailed May 14, 2026.Applicant